EP2346881A1 - Novel compounds which modulate kinase activity - Google Patents
Novel compounds which modulate kinase activityInfo
- Publication number
- EP2346881A1 EP2346881A1 EP09778867A EP09778867A EP2346881A1 EP 2346881 A1 EP2346881 A1 EP 2346881A1 EP 09778867 A EP09778867 A EP 09778867A EP 09778867 A EP09778867 A EP 09778867A EP 2346881 A1 EP2346881 A1 EP 2346881A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- radical
- heteroaryl
- phenyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 110
- 230000000694 effects Effects 0.000 title claims description 30
- 108091000080 Phosphotransferase Proteins 0.000 title claims description 27
- 102000020233 phosphotransferase Human genes 0.000 title claims description 27
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 32
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 28
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 27
- 125000003342 alkenyl group Chemical group 0.000 claims description 26
- 125000000304 alkynyl group Chemical group 0.000 claims description 26
- 125000003118 aryl group Chemical group 0.000 claims description 25
- 125000001072 heteroaryl group Chemical group 0.000 claims description 23
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 22
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 22
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 21
- 229910052757 nitrogen Inorganic materials 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 229910052717 sulfur Inorganic materials 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 125000006413 ring segment Chemical group 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 7
- 239000000651 prodrug Substances 0.000 claims description 6
- 229940002612 prodrug Drugs 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000006806 disease prevention Effects 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 abstract description 13
- 108060006633 protein kinase Proteins 0.000 abstract description 13
- 230000002255 enzymatic effect Effects 0.000 abstract description 3
- IAWSGYCQVBQFEW-UHFFFAOYSA-N C1=CNSC2=CN=NC2=C1 Chemical class C1=CNSC2=CN=NC2=C1 IAWSGYCQVBQFEW-UHFFFAOYSA-N 0.000 abstract description 2
- -1 small -molecule compounds Chemical class 0.000 description 80
- 125000004432 carbon atom Chemical group C* 0.000 description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
- 201000010099 disease Diseases 0.000 description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 19
- 238000000034 method Methods 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 15
- 229910052760 oxygen Inorganic materials 0.000 description 15
- 239000001301 oxygen Substances 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 11
- 239000000460 chlorine Substances 0.000 description 10
- 229910052801 chlorine Inorganic materials 0.000 description 10
- 229910052731 fluorine Inorganic materials 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 7
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 229910052794 bromium Inorganic materials 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 239000011737 fluorine Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- KNIHGGMBTCGEED-UHFFFAOYSA-N 4h-pyrazolo[3,4-e][1,4]thiazepine Chemical compound C1SC=CN=C2N=NC=C12 KNIHGGMBTCGEED-UHFFFAOYSA-N 0.000 description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 6
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 5
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- 230000012292 cell migration Effects 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 125000004475 heteroaralkyl group Chemical group 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 239000011593 sulfur Substances 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 4
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 4
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 229940043355 kinase inhibitor Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 229910052711 selenium Inorganic materials 0.000 description 4
- 239000011669 selenium Substances 0.000 description 4
- 229910052710 silicon Inorganic materials 0.000 description 4
- 239000010703 silicon Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 4
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000001828 Gelatine Substances 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 238000000021 kinase assay Methods 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000036983 biotransformation Effects 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004709 cell invasion Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- RWGFKTVRMDUZSP-UHFFFAOYSA-N cumene Chemical compound CC(C)C1=CC=CC=C1 RWGFKTVRMDUZSP-UHFFFAOYSA-N 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 229940068917 polyethylene glycols Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical compound N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- JIDDDPVQQUHACU-YFKPBYRVSA-N (2s)-pyrrolidine-2-carbaldehyde Chemical group O=C[C@@H]1CCCN1 JIDDDPVQQUHACU-YFKPBYRVSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical class C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- KEIFWROAQVVDBN-UHFFFAOYSA-N 1,2-dihydronaphthalene Chemical compound C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- MMZYCBHLNZVROM-UHFFFAOYSA-N 1-fluoro-2-methylbenzene Chemical compound CC1=CC=CC=C1F MMZYCBHLNZVROM-UHFFFAOYSA-N 0.000 description 1
- JQCSUVJDBHJKNG-UHFFFAOYSA-N 1-methoxy-ethyl Chemical group C[CH]OC JQCSUVJDBHJKNG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical compound NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 description 1
- HMBHAQMOBKLWRX-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)COC2=C1 HMBHAQMOBKLWRX-UHFFFAOYSA-N 0.000 description 1
- GZIJORHCTCOXOU-UHFFFAOYSA-N 2-(3-methyl-7-oxo-4-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl)-n-(2-morpholin-4-ylethyl)acetamide Chemical compound O=C1N=C2NNC(C)=C2C(C=2C=CC=CC=2)SC1CC(=O)NCCN1CCOCC1 GZIJORHCTCOXOU-UHFFFAOYSA-N 0.000 description 1
- YMRKIYJBRXJKEC-UHFFFAOYSA-N 2-(3-methyl-7-oxo-4-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl)acetic acid Chemical compound S1C(CC(O)=O)C(=O)N=C2NNC(C)=C2C1C1=CC=CC=C1 YMRKIYJBRXJKEC-UHFFFAOYSA-N 0.000 description 1
- LGGQVFPTXSJUGU-UHFFFAOYSA-N 2-(7-oxo-3,4-diphenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl)acetic acid Chemical compound N1NC2=NC(=O)C(CC(=O)O)SC(C=3C=CC=CC=3)C2=C1C1=CC=CC=C1 LGGQVFPTXSJUGU-UHFFFAOYSA-N 0.000 description 1
- REBWSFKBXIVNRQ-UHFFFAOYSA-N 2-(furan-3-yl)furan Chemical group C1=COC(C2=COC=C2)=C1 REBWSFKBXIVNRQ-UHFFFAOYSA-N 0.000 description 1
- VNGURXAPQZTOPS-UHFFFAOYSA-N 2-[3-(3-morpholin-4-ylphenyl)-7-oxo-4-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl]acetic acid Chemical compound N1NC2=NC(=O)C(CC(=O)O)SC(C=3C=CC=CC=3)C2=C1C(C=1)=CC=CC=1N1CCOCC1 VNGURXAPQZTOPS-UHFFFAOYSA-N 0.000 description 1
- XKELKBPNJYXTNB-UHFFFAOYSA-N 2-[3-(4-chlorophenyl)-4-[4-(morpholin-4-ylmethyl)phenyl]-7-oxo-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl]acetic acid Chemical compound N1NC2=NC(=O)C(CC(=O)O)SC(C=3C=CC(CN4CCOCC4)=CC=3)C2=C1C1=CC=C(Cl)C=C1 XKELKBPNJYXTNB-UHFFFAOYSA-N 0.000 description 1
- ZKAMEIYNBFJPBI-UHFFFAOYSA-N 2-[3-(4-chlorophenyl)-7-oxo-4-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl]-n-(3-morpholin-4-ylpropyl)acetamide Chemical compound C1=CC(Cl)=CC=C1C(NN1)=C2C1=NC(=O)C(CC(=O)NCCCN1CCOCC1)SC2C1=CC=CC=C1 ZKAMEIYNBFJPBI-UHFFFAOYSA-N 0.000 description 1
- DBNMVLXCLVXWJB-UHFFFAOYSA-N 2-[3-(4-chlorophenyl)-7-oxo-4-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl]acetic acid Chemical compound N1NC2=NC(=O)C(CC(=O)O)SC(C=3C=CC=CC=3)C2=C1C1=CC=C(Cl)C=C1 DBNMVLXCLVXWJB-UHFFFAOYSA-N 0.000 description 1
- JQDNGKLNQOFJNR-UHFFFAOYSA-N 2-[3-(4-fluorophenyl)-4-[4-(morpholin-4-ylmethyl)phenyl]-7-oxo-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl]acetic acid Chemical compound N1NC2=NC(=O)C(CC(=O)O)SC(C=3C=CC(CN4CCOCC4)=CC=3)C2=C1C1=CC=C(F)C=C1 JQDNGKLNQOFJNR-UHFFFAOYSA-N 0.000 description 1
- LUQGXXNEKWCWOD-UHFFFAOYSA-N 2-[3-(4-fluorophenyl)-7-oxo-4-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl]-n,n-dimethylacetamide Chemical compound N1NC2=NC(=O)C(CC(=O)N(C)C)SC(C=3C=CC=CC=3)C2=C1C1=CC=C(F)C=C1 LUQGXXNEKWCWOD-UHFFFAOYSA-N 0.000 description 1
- DSNYFRQWFQMHOU-UHFFFAOYSA-N 2-[3-(4-fluorophenyl)-7-oxo-4-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl]-n-(3-morpholin-4-ylpropyl)acetamide Chemical compound C1=CC(F)=CC=C1C(NN1)=C2C1=NC(=O)C(CC(=O)NCCCN1CCOCC1)SC2C1=CC=CC=C1 DSNYFRQWFQMHOU-UHFFFAOYSA-N 0.000 description 1
- PAJPYAVKNXAJIH-UHFFFAOYSA-N 2-[3-(4-fluorophenyl)-7-oxo-4-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl]acetic acid Chemical compound N1NC2=NC(=O)C(CC(=O)O)SC(C=3C=CC=CC=3)C2=C1C1=CC=C(F)C=C1 PAJPYAVKNXAJIH-UHFFFAOYSA-N 0.000 description 1
- UTHCWIBDGUITCB-UHFFFAOYSA-N 2-[3-(furan-2-yl)-7-oxo-4-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl]-n-(2-morpholin-4-ylethyl)acetamide Chemical compound C1COCCN1CCNC(=O)CC(C(N=C1NN2)=O)SC(C=3C=CC=CC=3)C1=C2C1=CC=CO1 UTHCWIBDGUITCB-UHFFFAOYSA-N 0.000 description 1
- JXIXKPJVHBEJQN-UHFFFAOYSA-N 2-[3-(furan-2-yl)-7-oxo-4-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl]acetic acid Chemical compound N1NC2=NC(=O)C(CC(=O)O)SC(C=3C=CC=CC=3)C2=C1C1=CC=CO1 JXIXKPJVHBEJQN-UHFFFAOYSA-N 0.000 description 1
- GJQVVXAWBLUKGW-UHFFFAOYSA-N 2-[4-(1h-indol-3-yl)-7-oxo-3-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl]-n-(2-morpholin-4-ylethyl)acetamide Chemical compound C1COCCN1CCNC(=O)CC(C(N=C1NN2)=O)SC(C=3C4=CC=CC=C4NC=3)C1=C2C1=CC=CC=C1 GJQVVXAWBLUKGW-UHFFFAOYSA-N 0.000 description 1
- XNHBVPAASPQSQF-UHFFFAOYSA-N 2-[4-(1h-indol-3-yl)-7-oxo-3-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl]acetic acid Chemical compound N1NC2=NC(=O)C(CC(=O)O)SC(C=3C4=CC=CC=C4NC=3)C2=C1C1=CC=CC=C1 XNHBVPAASPQSQF-UHFFFAOYSA-N 0.000 description 1
- KGJJXRVQUNOTAO-UHFFFAOYSA-N 2-[4-(4-acetamidophenyl)-7-oxo-3-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl]-n-(2-morpholin-4-ylethyl)acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1C2=C(C=3C=CC=CC=3)NNC2=NC(=O)C(CC(=O)NCCN2CCOCC2)S1 KGJJXRVQUNOTAO-UHFFFAOYSA-N 0.000 description 1
- PJULHKOZJOADJN-UHFFFAOYSA-N 2-[4-(4-acetamidophenyl)-7-oxo-3-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl]acetic acid Chemical compound C1=CC(NC(=O)C)=CC=C1C1C2=C(C=3C=CC=CC=3)NNC2=NC(=O)C(CC(O)=O)S1 PJULHKOZJOADJN-UHFFFAOYSA-N 0.000 description 1
- VURZNYOQUZLDBZ-UHFFFAOYSA-N 2-[4-(4-methoxycarbonylphenyl)-7-oxo-3-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl]acetic acid Chemical compound C1=CC(C(=O)OC)=CC=C1C1C2=C(C=3C=CC=CC=3)NNC2=NC(=O)C(CC(O)=O)S1 VURZNYOQUZLDBZ-UHFFFAOYSA-N 0.000 description 1
- QVXWMBLKRBYOSN-UHFFFAOYSA-N 2-[4-(4-methoxyphenyl)-7-oxo-3-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl]-n-(2-morpholin-4-ylethyl)acetamide Chemical compound C1=CC(OC)=CC=C1C1C2=C(C=3C=CC=CC=3)NNC2=NC(=O)C(CC(=O)NCCN2CCOCC2)S1 QVXWMBLKRBYOSN-UHFFFAOYSA-N 0.000 description 1
- KCRPTPUMPUORMB-UHFFFAOYSA-N 2-[4-(4-methoxyphenyl)-7-oxo-3-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl]acetic acid Chemical compound C1=CC(OC)=CC=C1C1C2=C(C=3C=CC=CC=3)NNC2=NC(=O)C(CC(O)=O)S1 KCRPTPUMPUORMB-UHFFFAOYSA-N 0.000 description 1
- RCXYFUZSYJUOAS-UHFFFAOYSA-N 2-[4-(4-methylsulfonylphenyl)-7-oxo-3-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl]-n-(2-morpholin-4-ylethyl)acetamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1C2=C(C=3C=CC=CC=3)NNC2=NC(=O)C(CC(=O)NCCN2CCOCC2)S1 RCXYFUZSYJUOAS-UHFFFAOYSA-N 0.000 description 1
- OTXDOXYVAZGGAM-UHFFFAOYSA-N 2-[4-(4-methylsulfonylphenyl)-7-oxo-3-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl]acetic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1C2=C(C=3C=CC=CC=3)NNC2=NC(=O)C(CC(O)=O)S1 OTXDOXYVAZGGAM-UHFFFAOYSA-N 0.000 description 1
- CPLNIVTZWRWZQE-UHFFFAOYSA-N 2-[4-[4-(2-methoxy-2-oxoethoxy)phenyl]-7-oxo-3-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl]acetic acid Chemical compound C1=CC(OCC(=O)OC)=CC=C1C1C2=C(C=3C=CC=CC=3)NNC2=NC(=O)C(CC(O)=O)S1 CPLNIVTZWRWZQE-UHFFFAOYSA-N 0.000 description 1
- XQFRPMCKQGNXCV-UHFFFAOYSA-N 2-[4-[4-(morpholin-4-ylmethyl)phenyl]-7-oxo-3-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl]acetic acid Chemical compound N1NC2=NC(=O)C(CC(=O)O)SC(C=3C=CC(CN4CCOCC4)=CC=3)C2=C1C1=CC=CC=C1 XQFRPMCKQGNXCV-UHFFFAOYSA-N 0.000 description 1
- WCJFJUFRHKCBGL-UHFFFAOYSA-N 2-[4-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-7-oxo-3-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl]acetic acid Chemical compound C1CN(C)CCN1CC1=CC=C(C2C3=C(NNC3=NC(=O)C(CC(O)=O)S2)C=2C=CC=CC=2)C=C1 WCJFJUFRHKCBGL-UHFFFAOYSA-N 0.000 description 1
- QVXDREVKHAAZMX-UHFFFAOYSA-N 2-[7-oxo-3-phenyl-4-(4-phenylmethoxyphenyl)-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl]acetic acid Chemical compound N1NC2=NC(=O)C(CC(=O)O)SC(C=3C=CC(OCC=4C=CC=CC=4)=CC=3)C2=C1C1=CC=CC=C1 QVXDREVKHAAZMX-UHFFFAOYSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- CFPZXKOFXWLAHV-UHFFFAOYSA-N 2H-1,4-thiazepin-7-one Chemical compound S1CC=NC=CC1=O CFPZXKOFXWLAHV-UHFFFAOYSA-N 0.000 description 1
- XTHJAWDMOVGNDO-UHFFFAOYSA-N 3,4-diphenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-7-one Chemical compound N1NC2=NC(=O)CSC(C=3C=CC=CC=3)C2=C1C1=CC=CC=C1 XTHJAWDMOVGNDO-UHFFFAOYSA-N 0.000 description 1
- MFDQFHIMODMZLT-UHFFFAOYSA-N 3-(3-morpholin-4-ylphenyl)-4-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-7-one Chemical compound N1NC2=NC(=O)CSC(C=3C=CC=CC=3)C2=C1C(C=1)=CC=CC=1N1CCOCC1 MFDQFHIMODMZLT-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- SFTCMLGFLLDBGL-UHFFFAOYSA-N 3-methyl-4-[4-(morpholin-4-ylmethyl)phenyl]-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-7-one Chemical compound S1CC(=O)N=C2NNC(C)=C2C1C(C=C1)=CC=C1CN1CCOCC1 SFTCMLGFLLDBGL-UHFFFAOYSA-N 0.000 description 1
- YMAUHTCGRMMHMR-UHFFFAOYSA-N 3-methyl-4-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-7-one Chemical compound S1CC(=O)N=C2NNC(C)=C2C1C1=CC=CC=C1 YMAUHTCGRMMHMR-UHFFFAOYSA-N 0.000 description 1
- VMRHGWNGLCYRLX-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)-3-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-7-one Chemical compound C1=C(OC)C(OC)=CC=C1C1C2=C(C=3C=CC=CC=3)NNC2=NC(=O)CS1 VMRHGWNGLCYRLX-UHFFFAOYSA-N 0.000 description 1
- MVFIQVSWMZJPBB-UHFFFAOYSA-N 4-(4-chlorophenyl)-3-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-7-one Chemical compound C1=CC(Cl)=CC=C1C1C2=C(C=3C=CC=CC=3)NNC2=NC(=O)CS1 MVFIQVSWMZJPBB-UHFFFAOYSA-N 0.000 description 1
- QPKYKEKQLGPUKS-UHFFFAOYSA-N 4-(4-morpholin-4-ylphenyl)-3-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-7-one Chemical compound N1NC2=NC(=O)CSC(C=3C=CC(=CC=3)N3CCOCC3)C2=C1C1=CC=CC=C1 QPKYKEKQLGPUKS-UHFFFAOYSA-N 0.000 description 1
- CNIRESIKFWJZQK-UHFFFAOYSA-N 4-[4-(morpholin-4-ylmethyl)phenyl]-3-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-7-one Chemical compound N1NC2=NC(=O)CSC(C=3C=CC(CN4CCOCC4)=CC=3)C2=C1C1=CC=CC=C1 CNIRESIKFWJZQK-UHFFFAOYSA-N 0.000 description 1
- NOGPWQVBWAXNBO-UHFFFAOYSA-N 4-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-3-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-7-one Chemical compound C1CN(C)CCN1CC1=CC=C(C2C3=C(NNC3=NC(=O)CS2)C=2C=CC=CC=2)C=C1 NOGPWQVBWAXNBO-UHFFFAOYSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- AAJNWNWRXDVCDX-UHFFFAOYSA-N 4H-pyrazolo[3,4-e][1,4]thiazepine-3-carboxamide Chemical class N1=NC(=C2C1=NC=CSC2)C(=O)N AAJNWNWRXDVCDX-UHFFFAOYSA-N 0.000 description 1
- SFMKTKLMOYOANE-UHFFFAOYSA-N 4H-pyrazolo[3,4-e]thiazepine Chemical compound N1=NC=C2C1=CC=NSC2 SFMKTKLMOYOANE-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- DEAFDFKJEJVFAP-UHFFFAOYSA-N 6-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-3,4-diphenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-7-one Chemical compound C1CN(C)CCN1C(=O)CC1C(=O)N=C2NNC(C=3C=CC=CC=3)=C2C(C=2C=CC=CC=2)S1 DEAFDFKJEJVFAP-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- KZBKCELBGWDVNS-UHFFFAOYSA-N 6-methyl-4-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-3-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-7-one Chemical compound N1NC2=NC(=O)C(C)SC(C=3C=CC(CN4CCN(C)CC4)=CC=3)C2=C1C1=CC=CC=C1 KZBKCELBGWDVNS-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 208000001783 Adamantinoma Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 201000005171 Cystadenoma Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 208000005917 Exostoses Diseases 0.000 description 1
- COGANHIFQFNSMZ-UHFFFAOYSA-N FC1=C(C(=C(C(=C1OC(=O)C=1N=NC2=NC=CSCC2=1)F)F)F)F Chemical class FC1=C(C(=C(C(=C1OC(=O)C=1N=NC2=NC=CSCC2=1)F)F)F)F COGANHIFQFNSMZ-UHFFFAOYSA-N 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Natural products OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000000527 Germinoma Diseases 0.000 description 1
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000002927 Hamartoma Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001005128 Homo sapiens LIM domain kinase 1 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 102100026023 LIM domain kinase 1 Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002538 Polyethylene Glycol 20000 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 239000012963 UV stabilizer Substances 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000005354 acylalkyl group Chemical group 0.000 description 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 201000000452 adenoid squamous cell carcinoma Diseases 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- HSMPSHPWCOOUJH-UHFFFAOYSA-N anilinyl Chemical group [NH]C1=CC=CC=C1 HSMPSHPWCOOUJH-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 238000011122 anti-angiogenic therapy Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 208000028922 artery disease Diseases 0.000 description 1
- 125000005018 aryl alkenyl group Chemical group 0.000 description 1
- 125000005015 aryl alkynyl group Chemical group 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229940075419 choline hydroxide Drugs 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 150000003997 cyclic ketones Chemical class 0.000 description 1
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclo-pentanone Natural products O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- FWFSEYBSWVRWGL-UHFFFAOYSA-N cyclohex-2-enone Chemical compound O=C1CCCC=C1 FWFSEYBSWVRWGL-UHFFFAOYSA-N 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- BGTOWKSIORTVQH-HOSYLAQJSA-N cyclopentanone Chemical compound O=[13C]1CCCC1 BGTOWKSIORTVQH-HOSYLAQJSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000006202 diisopropylaminoethyl group Chemical group [H]C([H])([H])C([H])(N(C([H])([H])C([H])([H])*)C([H])(C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002084 enol ethers Chemical class 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- DUYAAUVXQSMXQP-UHFFFAOYSA-N ethanethioic S-acid Chemical class CC(S)=O DUYAAUVXQSMXQP-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 125000006534 ethyl amino methyl group Chemical group [H]N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 108091071773 flk family Proteins 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000002503 granulosa cell Anatomy 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 125000004447 heteroarylalkenyl group Chemical group 0.000 description 1
- 125000005312 heteroarylalkynyl group Chemical group 0.000 description 1
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229960002163 hydrogen peroxide Drugs 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- QNXSIUBBGPHDDE-UHFFFAOYSA-N indan-1-one Chemical compound C1=CC=C2C(=O)CCC2=C1 QNXSIUBBGPHDDE-UHFFFAOYSA-N 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 239000008011 inorganic excipient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 150000002527 isonitriles Chemical class 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- AUHZEENZYGFFBQ-UHFFFAOYSA-N mesitylene Substances CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 1
- 125000001827 mesitylenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- JIQNWFBLYKVZFY-UHFFFAOYSA-N methoxycyclohexatriene Chemical compound COC1=C[C]=CC=C1 JIQNWFBLYKVZFY-UHFFFAOYSA-N 0.000 description 1
- HADPXCCHORXHGK-UHFFFAOYSA-N methyl 2-[4-[6-[2-(2-morpholin-4-ylethylamino)-2-oxoethyl]-7-oxo-3-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-4-yl]phenoxy]acetate Chemical compound C1=CC(OCC(=O)OC)=CC=C1C1C2=C(C=3C=CC=CC=3)NNC2=NC(=O)C(CC(=O)NCCN2CCOCC2)S1 HADPXCCHORXHGK-UHFFFAOYSA-N 0.000 description 1
- CSFKEKLLBFBROA-UHFFFAOYSA-N methyl 4-[6-[2-(2-morpholin-4-ylethylamino)-2-oxoethyl]-7-oxo-3-phenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-4-yl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C1C2=C(C=3C=CC=CC=3)NNC2=NC(=O)C(CC(=O)NCCN2CCOCC2)S1 CSFKEKLLBFBROA-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 238000006452 multicomponent reaction Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- PHLHALCGRMXJRI-UHFFFAOYSA-N n-(2-morpholin-4-ylethyl)-2-(7-oxo-3,4-diphenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl)acetamide Chemical compound C1COCCN1CCNC(=O)CC(C(N=C1NN2)=O)SC(C=3C=CC=CC=3)C1=C2C1=CC=CC=C1 PHLHALCGRMXJRI-UHFFFAOYSA-N 0.000 description 1
- ZXJLLKSFUDNYEN-UHFFFAOYSA-N n-(2-morpholin-4-ylethyl)-2-[7-oxo-3-phenyl-4-(4-phenylmethoxyphenyl)-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl]acetamide Chemical compound C1COCCN1CCNC(=O)CC(C(N=C1NN2)=O)SC(C=3C=CC(OCC=4C=CC=CC=4)=CC=3)C1=C2C1=CC=CC=C1 ZXJLLKSFUDNYEN-UHFFFAOYSA-N 0.000 description 1
- RPXIYRIZAGSSNC-UHFFFAOYSA-N n-(3-morpholin-4-ylpropyl)-2-(7-oxo-3,4-diphenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl)acetamide Chemical compound C1COCCN1CCCNC(=O)CC(C(N=C1NN2)=O)SC(C=3C=CC=CC=3)C1=C2C1=CC=CC=C1 RPXIYRIZAGSSNC-UHFFFAOYSA-N 0.000 description 1
- AOPVKSZMCSXSNJ-UHFFFAOYSA-N n-(4-morpholin-4-ylbutyl)-2-(7-oxo-3,4-diphenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl)acetamide Chemical compound C1COCCN1CCCCNC(=O)CC(C(N=C1NN2)=O)SC(C=3C=CC=CC=3)C1=C2C1=CC=CC=C1 AOPVKSZMCSXSNJ-UHFFFAOYSA-N 0.000 description 1
- SLZCGDSOCTZKCW-UHFFFAOYSA-N n-[2-(4-methylpiperazin-1-yl)ethyl]-2-(7-oxo-3,4-diphenyl-2,4-dihydro-1h-pyrazolo[3,4-e][1,4]thiazepin-6-yl)acetamide Chemical compound C1CN(C)CCN1CCNC(=O)CC1C(=O)N=C2NNC(C=3C=CC=CC=3)=C2C(C=2C=CC=CC=2)S1 SLZCGDSOCTZKCW-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 150000002825 nitriles Chemical group 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- OIPZNTLJVJGRCI-UHFFFAOYSA-M octadecanoyloxyaluminum;dihydrate Chemical compound O.O.CCCCCCCCCCCCCCCCCC(=O)O[Al] OIPZNTLJVJGRCI-UHFFFAOYSA-M 0.000 description 1
- 208000004128 odontoma Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000008012 organic excipient Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 208000013368 pseudoglandular squamous cell carcinoma Diseases 0.000 description 1
- 230000001003 psychopharmacologic effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 210000002107 sheath cell Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- ZNJHFNUEQDVFCJ-UHFFFAOYSA-M sodium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[Na+].OCCN1CCN(CCS(O)(=O)=O)CC1 ZNJHFNUEQDVFCJ-UHFFFAOYSA-M 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 210000003684 theca cell Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 150000004912 thiazepines Chemical class 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 201000004916 vulva carcinoma Diseases 0.000 description 1
- 208000013013 vulvar carcinoma Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- Novel compounds which modulate kinase activity
- the present invention provides compounds that inhibit or modulate the enzymatic activity of protein kinases for modulating cellular activities such as proliferation, differentiation, programmed cell death, and migration.
- the invention provides novel compounds (e.g. pyrazolothiazepines) which inhibit, regulate and/or modulate kinase related signal transduction pathways resulting in changes of cellular activities, compositions which contain these compounds, and methods of using them to treat diseases and conditions that are related to kinase activities.
- novel compounds e.g. pyrazolothiazepines
- the present invention also provides methods for the preparation of these compounds, and compositions containing these compounds.
- New agents used to treat cancer are of considerable interest because a large variety of these neoplastic diseases have only poor and insufficient treatments. Improvements in the treatment of cancer are associated with identification of therapeutic agents acting through novel mechanisms, modulating cell signaling pathways.
- Protein kinases catalyze protein phosphorylation. The consequences of this activity are for example cell differentiation and proliferation - cell function depends greatly on protein kinase activity. Furthermore, abnormal protein kinase activity has been related to a range of disorders, ranging from relatively non-life threatening diseases such as psoriasis to extremely life threatening diseases such as brain cancer.
- the non-receptor type of tyrosine kinases comprises numerous subfamilies, including AbI, Src, Frk, Btk, Csk, Zap70, Fak, Jak, Ack, and LIMK. Each of these subfamilies contains a variety of kinases, for the Src subfamily includes Src, Yes, Fyn, Lyn, Lck, BIk, Hck, Fgr, Yrk known to promote oncogenesis .
- Deregulation of protein kinase enzymatic activity through overexpression, mutation and other pathways may lead to undesired cellular properties, such as proliferation, differentiation, programmed cell death, and migration.
- Altered kinase signaling is also included in immunological disorders, cardiovascular diseases, inflammatory diseases, and degenerative diseases.
- protein kinases are attractive drug targets for small molecule drug discovery and several kinase inhibitors are effective therapeutics. For example, as demonstrated successfully with the approval of the c-Kit and AbI kinase inhibitor Gleevec for the treatment of Chronic Myeloid Leukemia (CML) and gastrointestinal stroma cancers (GIST) .
- CML Chronic Myeloid Leukemia
- GIST gastrointestinal stroma cancers
- antiangiogenic therapy may represent an important approach for the treatment of solid tumors and other diseases associated with overtly active vascularization, such as but not limited to ischemic coronary ' artery disease, diabetic retinopathy, psoriasis and rheumatoid arthritis.
- kinases are biological targets for small -molecule modulation of angiogenic and proliferative activity, such as for example the receptor kinase c-Met.
- c-Met occurs in a wide variety of. cell types including epithelial, endothelial and mesenchymal cells inducing cell migration, invasion, proliferation and other biological activities associated with invasive cell growth.
- the hepatocyte growth factor (HGF), "scatter factor" (SF) as the endogenous ligand for c-Met is a potent inducer of angiogenesis and tumor growth.
- Anti-HGF antibodies or HGF antagonists and gene therapy have been shown to inhibit tumor metastasis in vivo (Matsumoto and Nakamura Cancer Science 2003, 94, 321-327) .
- c- Kit Another attractive target for small-molecule modulation is c- Kit .
- c-Kit is expressed in mast cells, immature myeloid cells, melanocytes, epithelial breast cells and the interstitial cells. In mast cells, it is required for differentiation, maturation, chemotaxis, and for the promotion of survival and proliferation.
- Flt-3 is a kinase that is constitutively activated via mutation in a large proportion of acute myeloid leukemia (AML) patients and correlated with poor prognosis in AML patients (Sawyers Cancer Cell 2002, 1, 413-415) .
- AML acute myeloid leukemia
- small -molecule compounds that specifically inhibit, regulate and/or modulate the signal transduction of kinases, including c-Met, KDR, c-Kit, Flt-3, and Flt-4, and others are desirable as agents to treat or prevent disease states associated with abnormal cell signaling through those kinases.
- kinase inhibitors that exhibit a therapeutically useful inhibition profile and specificity against a range of kinases (Goldstein et al . Nature Reviews Drug Discovery 2008, 7, 391-397) .
- the present invention provides one or more compounds for modulating kinase activity and one or more methods of treating and/or preventing one or more diseases mediated by kinase activity utilizing the compound (s) and pharmaceutical composition (s) thereof.
- Diseases mediated by kinase activity include, but are not limited to, diseases characterized in part by cell migration, invasion, proliferation and other biological activities associated with invasive cell growth.
- this invention relates to modulation, especially inhibition, of c-Met, KDR, c-Kit, flt- 3, and flt-4.
- the invention also provides one or more pharmaceutical formulations comprising one or more compounds and/or pharmaceutical compositions of the present invention, as described herein.
- Such pharmaceutical formulations can also include one or more other compounds or compositions (for example diluents, permeation enhancers, lubricants, and the like) .
- the present invention provides a process for making a compound, and pharmaceutical composition thereof, for modulating kinase activity and treating diseases mediated by kinase activity.
- this invention also relates to a method for making a pyrazolo [3 , 4- e] [1 , 4] thiazepine used for modulation of kinase activity, even more particular inhibition of kinase activity, and yet even more particular inhibition of c-Met, KDR, c-Kit, flt-3, and flt-4.
- the composition of the invention is used to treat one or more diseases related to abnormal cellular activities.
- Diseases which can be treated by the methods and compositions provided herein include, but are not limited to, various forms of neoplastic diseases, immunological disorders such as rheumatoid arthritis, graft-host diseases, multiple sclerosis, psoriasis; cardiovascular diseases such as artheroscrosis, myocardioinfarction, ischemia, stroke and restenosis; other inflammatory and degenerative diseases such as interbowel diseases, macular degeneration and diabetic retinopathy.
- the cells may exhibit abnormal cellular activities and still require treatment.
- cells may be proliferating "normally”, but proliferation and migration enhancement may be desired.
- reduction in "normal” cell proliferation and/or migration rate may be desired.
- X is S, SO or SO 2 ;
- R 1 is a hydrogen atom or an alkyl, alkenyl, alkynyl, hetero- alkyl, aryl , heteroaryl, cycloalkyl, alkylcycloalkyl , heteroalkylcycloalkyl , heterocycloalkyl , aralkyl or hetero- aralkyl radical;
- R 2 is a hydrogen atom or an alkyl, alkenyl, alkynyl, hetero- alkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl , heteroalkylcycloalkyl, heterocycloalkyl, aralkyl or hetero- aralkyl radical;
- R 3 is a hydrogen atom or an alkyl, alkenyl, alkynyl, hetero- alkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl or hetero- aralkyl radical;
- R 4 is a hydrogen atom or an alkyl, alkenyl, alkynyl, hetero- alkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl or hetero- aralkyl radical; and R 5 is a hydrogen atom or an alkyl, alkenyl , alkynyl, hetero- alkyl, aryl , heteroaryl , cycloalkyl, alkylcycloalkyl , heteroalkylcycloalkyl, heterocycloalkyl , aralkyl or heteroaralkyl radical;
- alkyl refers to a saturated, straight-chain or branched hydrocarbon group that contains from 1 to 20 carbon atoms, preferably from 1 to 12 carbon atoms, especially from 1 to 6 (e.g. 1, 2, 3 or 4) carbon atoms, for example a methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert -butyl, n-pentyl, iso-pentyl, n-hexyl, 2 , 2-dimethylbutyl or n-octyl group.
- alkenyl and alkynyl refer to at least partially unsaturated, straight-chain or branched hydrocarbon groups that contain from 2 to 20 carbon atoms, preferably from 2 to 12 carbon atoms, especially from 2 to 6 (e.g. 2, 3 or 4) carbon atoms, for example an ethenyl (vinyl) , propenyl
- alkenyl groups have one or two (especially preferably one) double bond(s)
- alkynyl groups have one or two
- alkyl, alkenyl and alkynyl refer to groups in which one or more hydrogen atoms have been replaced e.g. by a halogen atom (preferably F or Cl) such as, for example, a 2 , 2 , 2-trichloroethyl or a trifluoromethyl group.
- a halogen atom preferably F or Cl
- heteroalkyl refers to an alkyl , alkenyl or alkynyl group in which one or more (preferably 1, 2 or 3) carbon atoms, each independently, have been replaced by an oxygen, nitrogen, phosphorus, boron, selenium, silicon or sulfur atom (preferably by an oxygen, sulfur or nitrogen atom) .
- the expression heteroalkyl furthermore refers to a carboxylic acid or to a group derived from a carboxylic acid, such as, for example, acyl , acylalkyl, alkoxycarbonyl , acyloxy, acyloxyalkyl , carboxyalkylamide or alkoxycarbonyloxy.
- a heteroalkyl group contains from 1 to 12 carbon atoms and from 1 to 4 hetero atoms selected from oxygen, nitrogen and sulphur (especially oxygen and nitrogen) .
- a heteroalkyl group contains from 1 to 6 (e.g. 1, 2, 3 or 4) carbon atoms and 1, 2 or 3 (especially 1 or 2) hetero atoms selected from oxygen, nitrogen and sulphur (especially oxygen and nitrogen) .
- heteroalkyl groups are groups of formulae: R a -O-Y a -, R a -S-Y a -, R a -N(R b ) -Y a -, R a -CO-Y a -, R a -O-CO-Y a -, R a -CO-O-Y a -, R a -CO-N(R b ) -Y a - , R a -N (R b ) -CO-Y a - , R a -O-CO-N (R b ) -Y a - , R a -N (R b ) -CO-O-Y a - , R a -N (R b ) -CO-O-Y a - , R a -N (R b ) -CO-O-Y a - , R a -N (R
- heteroalkyl groups are methoxy, trifluoromethoxy, ethoxy, n-propyloxy, isopropyloxy, butoxy, tert-butyloxy, methoxymethyl , ethoxymethyl , -CH 2 CH 2 OH, -CH 2 OH, methoxyethyl , 1-methoxyethyl , 1-ethoxyethyl , 2 -methoxyethyl or 2-ethoxyethyl, methylamino, ethylamino, propylamino, isopropylamino, dimethylamino, diethylamino, isopropyl- ethylamino, methylamino methyl, ethylamino methyl, diiso- propylamino ethyl, methylthio, ethylthio, isopropylthio, enol ether, dimethylamino methyl, dimethyla
- cycloalkyl refers to a saturated or partially unsaturated (for example, a cycloalkenyl group) cyclic group that contains one or more rings (preferably 1 or 2), and contains from 3 to 14 ring carbon atoms, preferably from 3 to 10 (especially 3, 4, 5, 6 or 7) ring carbon atoms.
- cycloalkyl groups are a cyclopropyl, cyclobutyl, cyclopentyl, spiro [4 , 5] decanyl , norbornyl , cyclohexyl, cyclopentenyl , cyclohexadienyl , decalinyl, bicyclo [4.3.0] nonyl , tetraline, cyclopentylcyclohexyl , fluorocyclohexyl or cyclohex-2-enyl group .
- heterocycloalkyl refers to a cycloalkyl group as defined above in which one or more (preferably 1, 2 or 3) ring carbon atoms, each independently, have been replaced by an oxygen, nitrogen, silicon, selenium, phosphorus or sulfur atom (preferably by an oxygen, sulfur or nitrogen atom) .
- a heterocycloalkyl group has preferably 1 or 2 ring(s) containing from 3 to 10 (especially 3, 4, 5, 6 or 7) ring atoms (preferably secected from C, 0, N and S) .
- Examples are a piperidyl, prolinyl, imidazolidinyl , piperazinyl, morpholinyl, urotropinyl, pyrrolidinyl , tetra- hydrothiophenyl, tetrahydropyranyl , tetrahydrofuryl or 2-pyrazolinyl group and also lactames, lactones, cyclic imides and cyclic anhydrides.
- alkylcycloalkyl refers to a group that contains both cycloalkyl and also alkyl, alkenyl or alkynyl groups in accordance with the above definitions, for example alkylcycloalkyl, cycloalkylalkyl , alkylcycloalkenyl , alkenylcycloalkyl and alkynylcycloalkyl groups.
- An alkylcycloalkyl group preferably contains a cycloalkyl group that contains one or two ring systems having from 3 to 10 (especially 3, 4, 5, 6 or 7) ring carbon atoms, and one or two alkyl, alkenyl or alkynyl groups having 1 or 2 to 6 carbon atoms .
- heteroalkylcycloalkyl refers to alkylcycloalkyl groups as defined above in which one or more (preferably 1, 2 or 3) carbon atoms, each independently, have been replaced by an oxygen, nitrogen, silicon, selenium, phosphorus or sulfur atom (preferably by an oxygen, sulfur or nitrogen atom) .
- a heteroalkylcycloalkyl group preferably contains 1 or 2 ring systems having from 3 to 10 (especially 3, 4, 5, 6 or 7) ring atoms, and one or two alkyl, alkenyl, alkynyl or heteroalkyl groups having from 1 or 2 to 6 carbon atoms.
- alkylheterocycloalkyl examples include alkylheterocycloalkyl , alkylheterocycloalkenyl , alkenylheterocycloalkyl , alkynylheterocycloalkyl , heteroalkylcycloalkyl, heteroalkylheterocycloalkyl and hetero- alkylheterocycloalkenyl, the cyclic groups being saturated or mono-, di- or tri -unsaturated.
- aryl or Ar refers to an aromatic group that contains one or more rings containing from 6 to 14 ring carbon atoms, preferably from 6 to 10 (especially 6) ring carbon atoms.
- aryl (or Ar, respectively) refers furthermore to groups in which one or more hydrogen atoms have been replaced by fluorine, chlorine, bromine or iodine atoms or by OH, SH, NH 2 , N 3 or NO 2 groups. Examples are the phenyl, naphthyl , biphenyl , 2-fluorophenyl , anilinyl, 3 -nitrophenyl or 4 -hydroxyphenyl group .
- heteroaryl refers to an aromatic group that contains one or more rings containing from 5 to 14 ring atoms, preferably from 5 to 10 (especially 5 or 6) ring atoms, and contains one or more (preferably 1, 2, 3 or 4) oxygen, nitrogen, phosphorus or sulfur ring atoms (preferably 0, S or N) .
- heteroaryl refers furthermore to groups in which one or more hydrogen atoms have been replaced by fluorine, chlorine, bromine or iodine atoms or by OH, SH, N 3 , NH 2 or NO 2 groups. Examples are pyridyl (e.g. 4-pyridyl) , imidazolyl (e.g.
- 2-imidazolyl) phenylpyrrolyl (e.g. 3- phenylpyrrolyl) , thiazolyl, isothiazolyl , 1 , 2 , 3-triazolyl , 1 , 2 , 4-triazolyl , oxadiazolyl , thiadiazolyl , indolyl , indazolyl, tetrazolyl, pyrazinyl, pyrimidinyl , pyridazinyl, oxazolyl , isoxazolyl, triazolyl, tetrazolyl, isoxazolyl, indazolyl, indolyl, benzimidazolyl , benzoxazolyl , benzisoxazolyl , benzthiazolyl , pyridazinyl, quinolinyl, isoquinolinyl , pyrrolyl, purinyl , carb
- aralkyl refers to a group containing both aryl and also alkyl, alkenyl, alkynyl and/or cycloalkyl groups in accordance with the above definitions, such as, for example, an arylalkyl, arylalkenyl , arylalkynyl, aryleye1oalkyl , aryl- cycloalkenyl , alkylarylcycloalkyl and alkylarylcycloalkenyl group.
- aralkyls are toluene, xylene, mesitylene, styrene, benzyl chloride, o-fluorotoluene, lH-indene, tetraline, dihydronaphthalene, indanone, phenylcyclopentyl , cumene, cyclohexylphenyl , fluorene and indane.
- An aralkyl group preferably contains one or two aromatic ring systems (1 or 2 rings) containing from 6 to 10 carbon atoms and one or two alkyl , alkenyl and/or alkynyl groups containing from 1 or 2 to 6 carbon atoms and/or a cycloalkyl group containing 5 or 6 ring carbon atoms .
- heteroaralkyl refers to an aralkyl group as defined above in which one or more (preferably 1, 2, 3 or 4) carbon atoms, each independently, have been replaced by an oxygen, nitrogen, silicon, selenium, phosphorus, boron or sulfur atom (preferably oxygen, sulfur or nitrogen) , that is to say to a group containing both aryl or heteroaryl, respectively, and also alkyl, alkenyl, alkynyl and/or heteroalkyl and/or cycloalkyl and/or heterocycloalkyl groups in accordance with the above definitions.
- a heteroaralkyl group preferably contains one or two aromatic ring systems (1 or 2 rings) containing from 5 or 6 to 10 ring carbon atoms and one or two alkyl, alkenyl and/or alkynyl groups containing 1 or 2 to 6 carbon atoms and/or a cycloalkyl group containing 5 or 6 ring carbon atoms, wherein 1, 2, 3 or 4 of these carbon atoms have been replaced by oxygen, sulfur or nitrogen atoms.
- Examples are arylheteroalkyl , arylheterocycloalkyl , aryl- heterocycloalkenyl , arylalkylheterocycloalkyl , arylalkenyl- heterocycloalkyl , arylalkynylheterocycloalkyl, arylalkyl- heterocycloalkenyl , heteroarylalkyl , heteroarylalkenyl , heteroarylalkynyl, heteroarylheteroalkyl , heteroaryl - cycloalkyl, heteroarylcycloalkenyl , heteroarylhetero- cycloalkyl, heteroarylheterocycloalkenyl , heteroarylalkyl - cycloalkyl, heteroarylalkylheterocycloalkenyl , heteroarylalkyl - cycloalkyl, heteroarylalkylheterocycloalkenyl
- This expression refers furthermore to a group that are substituted by one, two, three or more (preferably unsubstituted) Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl , Ci-C 6 heteroalkyl, C 3 -Ci 0 cycloalkyl, C 2 -C 9 heterocycloalkyl, C 2 -Ci 2 alkylcycloalkyl , C 2 -Cn hetero- alkylcycloalkyl C 6 -Ci 0 aryl , Ci-C 9 heteroaryl, C 7 -Ci 2 aralkyl or C 2 -Cn heteroaralkyl groups.
- all alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkylcycloalkyl , heteroalkylcycloalkyl, aralkyl and heteroaralkyl groups described herein may optionally be substituted.
- R 1 is an optionally substituted aryl or heteroaryl or an alkyl radical.
- R 1 is an optionally substituted phenyl radical or an optionally substituted heteroaryl radical containing 5 or 6 ring atoms and 1, 2, 3 or 4 heteroatoms selected from 0, S and N.
- R 1 has the following structure wherein the groups R 6 are independently from each other a halogen atom or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl , heteroaryl , cycloalkyl, alkylcycloalkyl , heteroalkylcyclo- alkyl, heterocycloalkyl , aralkyl or heteroaralkyl radical and m is 0, 1, 2, 3, 4 or 5 (especially 0 or 1) .
- R 6 is F, Cl, Br, CN, NHCOMe, Me, OMe, CF 3 or OCF 3 .
- R 2 is an optionally substituted aryl or heteroaryl radical .
- R 2 is an optionally substituted phenyl or naphthyl radical or an optionally substituted heteroaryl radical containing 5 or 6 to 10 ring atoms (i.e. one or two rings) and 1, 2, 3 or 4 heteroatoms selected from 0, S and N.
- R 2 has the following structure wherein the groups R 7 are independently from each other a halogen atom or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcyclo- alkyl, heterocycloalkyl, aralkyl or heteroaralkyl radical and o is 0, 1, 2, 3, 4 or 5 (especially 0, 1 or 2) .
- R 7 is F, Cl, OMe, Me, SO 2 Me, NHCOMe, COOH, COOMe, OCH 2 COOMe, OCH 2 COOH, benzyl, a heterocycloalkyl (e.g. a morpholinyl or a piperazinyl) radical, or an heteroalkylcycloalkyl (e.g. a -CH 2 -morpholinyl, -CH 2 - piperazinyl, -CH 2 -N-Methylpiperazinyl or an N-methyl- piperazinyl) radical.
- a heterocycloalkyl e.g. a morpholinyl or a piperazinyl
- an heteroalkylcycloalkyl e.g. a -CH 2 -morpholinyl, -CH 2 - piperazinyl, -CH 2 -N-Methylpiperazinyl or an N-methyl- piperazinyl
- R 3 is a hydrogen atom or Ci-C 4 alkyl, especially hydrogen.
- R 4 is a hydrogen atom or an alkyl, heteroalkyl or a heteroalkylcycloalkyl radical .
- R 4 is hydrogen, Ci-C 4 alkyl or a group of formula CH 2 COR 8 wherein R 8 is hydroxy or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl , heteroaryl, cycloalkyl, alkylcycloalkyl , heteroalkylcycloalkyl, heterocycloalkyl , aralkyl or heteroaralkyl radical; especially preferably, R 8 is hydroxy or NH (CH 2 ) P R 9 , wherein p is 0, 1, 2, 3 or 4 and R 9 is a heterocycloalkyl radical (preferably containing 5 or 6 ring atoms and 1, 2, 3 or 4 heteroatoms selected from 0, S and N) .
- R 8 is hydroxy or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl , heteroaryl, cycloalkyl, alkylcycloalkyl , heteroalkylcycloalkyl, heterocycloal
- the compounds of formula (I) are selected from the following compounds:
- R is hydrogen, loweralkyl or phenyl
- R 2 is loweralkyl, cyclopropyl, 2-furyl or , wherein X is hydrogen, halogen, trifluoromethyl , hydroxy, loweralkoxy or dimethylamino and Y is hydrogen, chlorine or loweralkoxy, R 3 is hydrogen or loweralkyl,
- R 4 is hydrogen, loweralkyl or carboxyloweralkyl
- R 5 is hydrogen, loweralkyl or diloweralkylamino- loweralkyl ; wherein the term “loweralkyl” or “loweralkoxy” is intended to refer to saturated hydrocarbon chains of 1 - 7 carbon atoms .
- a compound of formula (I) is used to modulate kinase activity.
- Another aspect of the invention is a metabolite of a compound of formula (I) or a pharmaceutical composition thereof.
- Another aspect of the invention is a pharmaceutical composition
- a pharmaceutical composition comprising a compound of Formula (I) and a pharmaceutically acceptable carrier.
- the present invention further relates to a method of modulating the in vivo activity of a kinase, by administering to a mammal an effective amount of the compound of Formula (I) or the pharmaceutical composition containing a compound of Formula (I) .
- Another aspect of the present invention relates to a method, wherein modulating the in vivo activity of a kinase comprises inhibition of said kinase.
- Another aspect of the invention is a method of modulating the in vivo activity of a kinase, the method comprising administering to a subject an effective amount of the compound or the pharmaceutical composition described herein, wherein preferentially modulating the in vivo activity of the kinase comprises inhibition of said kinase, more preferentially wherein the kinase is at least one of c-Met, KDR, c-Kit, flt- 3, and flt-4.
- Another aspect of the invention is a method of treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of the compound or the pharmaceutical composition as described.
- the present invention further relates to a method of inhibiting proliferative activity in a cell, the method comprising administering an effective amount of a compound of Formula (I) to a cell or a plurality of cells.
- the present invention further relates to a method of treating mammalian diseases or disorders associated with abnormal and unwanted cellular activities, the method comprising administering to a mammal a therapeutically effective amount of one or more compounds of Formula (I) .
- the present invention further relates to a process for preparing a compound of Formula (I) , wherein an aminopyrazole, an aldehyde and a thioacetic acid derivative are reacted together, optionally in the presence of a base, optionally with heating or microwave radiation, to form compounds of Formula (I) .
- the present invention further relates to a process for preparing a compound of Formula (I), wherein a compound of
- Formula (I) is reacted with further compounds to form derivatives of Formula (I) .
- metabolite refers to a product of a compound of Formula (I) produced by metabolism or biotransformation in the animal or human body; for example, biotransformation to a more polar molecule such as by oxidation, reduction, or hydrolysis, or to a conjugate (see Goodman and Gilman, "The Pharmacological Basis of Therapeutics” 8 th Ed., Pergamon Press, Gilman et al . , (eds) , 1990) .
- the metabolite of a compound of the invention or its salt may be the biologically active form of the compound in the body.
- a prodrug may be used such that the biologically active form, a metabolite, is released in vivo.
- Such metabolites are also encompassed within the scope of the present invention.
- Examples of pharmacologically acceptable salts of sufficiently basic compounds of formula (I) are salts of physiologically acceptable mineral acids like hydrochloric, hydrobromic, sulfuric and phosphoric acid; or salts of organic acids like methanesulfonic, p-toluenesulfonic, lactic, acetic, trifluoroacetic, citric, succinic, fumaric, maleic and salicylic acid.
- a sufficiently acidic compound of formula (I) may form alkali or earth alkaline metal salts, for example sodium, potassium, lithium, calcium or magnesium salts; ammonium salts; or organic base salts, for example methylamine, dimethylamine, trimethylamine, triethylamine, ethylenediamine, ethanolamine, choline hydroxide, meglumin, piperidine, morpholine, tris- (2 -hydroxyethyl) amine, lysine or arginine salts; all of which are also further examples of salts of formula (I) .
- Compounds of formula (I) may be solvated, especially hydrated.
- the hydratization/hydration may occur during the process of production or as a consequence of the hygroscopic nature of the initially water free compounds of formula (I) .
- the solvates and/or hydrates may e.g. be present in solid or liquid form.
- certain compounds of formula (I) may have tautomeric forms from which only one might be specifically mentioned or depicted in the following description, different geometrical isomers (which are usually denoted as cis/trans isomers or more generally as (E) and (Z) isomers) or different optical isomers as a result of one or more chiral carbon atoms (which are usually nomenclatured under the Cahn-Ingold-Prelog or R/S system) . All these tautomeric forms, geometrical or optical isomers (as well as racemates and diastereomers) and polymorphous forms are included in the invention.
- the compounds of formula (I) may contain asymmetric C-atoms, they may be present either as achiral compounds, mixtures of diastereomers, mixtures of enantiomers or as optically pure compounds.
- the present invention comprises both all pure enantiomers and all pure diastereomers, and also the mixtures thereof in any mixing ratio .
- E.g. compounds of formula (I) may have imino, amino, oxo or hydroxy substituents off aromatic heterocyclic systems.
- imino, amino, oxo or hydroxy substituents may exist in their corresponding tautomeric form, i.e., as amino, imino, hydroxy or oxo, respectively.
- compositions according to the present invention comprise at least one compound of formula (I) as an active ingredient and, optionally, carrier substances and/or adjuvants .
- the present invention also relates to pro-drugs which are composed of a compound of formula (I) and at least one pharmacologically acceptable protective group which will be cleaved off under physiological conditions, such as an alkoxy-, arylalkyloxy- , acyl-, acyloxymethyl group (e.g. pivaloyloxymethyl) , an 2-alkyl-, 2-aryl- or 2-arylalkyl- oxycarbonyl-2-alkylidene ethyl group or an acyloxy group as defined herein, e.g.
- a compound of formula (I) carrying a hydroxy group (-OH) : a sulfate, a phosphate (-OPO 3 or OCH 2 OPO 3 ) or an ester of an amino acid.
- pro-drugs of the hydroxy group of a compound of formula (I) are especially preferred.
- therapeutically useful agents that contain compounds of formula (I) , their solvates, salts or formulations are also comprised in the scope of the present invention.
- compounds of formula (I) will be administered by using the known and acceptable modes known in the art, either alone or in combination with any other therapeutic agent.
- such therapeutically useful agents can be administered by one of the following routes: oral, e.g. as tablets, dragees, coated tablets, pills, semisolids, soft or hard capsules, for example soft and hard gelatine capsules, aqueous or oily solutions, emulsions, suspensions or syrups, parenteral including intravenous, intramuscular and subcutaneous injection, e.g. as an injectable solution or suspension, rectal as suppositories, by inhalation or insufflation, e.g. as a powder formulation, as microcrystals or as a spray (e.g.
- liquid aerosol transdermal
- TDS transdermal delivery system
- the therapeutically useful product may be mixed with pharmaceutically inert, inorganic or organic excipients as are e.g. lactose, sucrose, glucose, gelatine, malt, silica gel, starch or derivatives thereof, talc, stearinic acid or their salts, dried skim milk, and the like.
- pharmaceutically inert, inorganic or organic excipients as are e.g. lactose, sucrose, glucose, gelatine, malt, silica gel, starch or derivatives thereof, talc, stearinic acid or their salts, dried skim milk, and the like.
- excipients e.g.
- excipients e.g. water, alcohols, aqueous saline, aqueous dextrose, polyols, glycerin, lipids, phospholipids, cyclodextrins, vegetable, petroleum, animal or synthetic oils.
- lipids and more preferred are phospholipids (preferred of natural origin; especially preferred with a particle size between 300 to 350 nm) preferred in phosphate buffered saline (pH 7 to 8, preferred 7.4) .
- excipients as are e.g.
- the pharmaceutically useful agents may also contain additives for conservation, stabilization, e.g. UV stabilizers, emulsifiers, sweetener, aromatizers, salts to change the osmotic pressure, buffers, coating additives and antioxidants .
- stabilization e.g. UV stabilizers, emulsifiers, sweetener, aromatizers, salts to change the osmotic pressure, buffers, coating additives and antioxidants .
- Compounds of formula (I) of the present invention may be used for the treatment and/or prevention of the following diseases:
- cancer tumor growth
- pathologic neovascularization that supports solid tumor growth
- other diseases where excessive local vascularization is involved such as ocular diseases (diabetic retinopathy, age-related macular degeneration, and the like) and inflammation (psoriasis, rheumatoid arthritis, and the like) .
- the present invention relates to the use of compounds of formula (I) for the preparation of medicaments for the treatment and/or prevention of the diseases described herein.
- the daily dosage can be administered as a single dose or in divided doses, or for parenteral administration, it may be given as continuous infusion or subcutaneous injection.
- a therapeutically effective amount of a compound in accordance with this invention means an amount of compound that is effective to prevent, alleviate or ameliorate symptoms of disease or prolongs the survival of the subject being treated. Determination of a therapeutically effective amount is within the skill in the art.
- the therapeutically effective amount or dosage of a compound according to this invention can vary within wide limits and may be determined in a manner known in the art . Such dosage may be adjusted to the individual requirements in each particular case including the specific compound being administered, the route of administration, the condition being treated, as well as the patient being treated.
- cancer refers to cellular- proliferative disease states, benign and malignant tumours that are solid or cystic in nature, adenomas, cystadenomas, papilloimas, adenocarcinonmas, adenocarcinonmas of the cirrhotic typo, basal cell carcinomas, sarcomas, fibrosarcomas, liposarcomas, lymphosarcomas, rhabdomyosarcomas, myxosarcomas, chondrosarcomas, reticulum cell sarcomas, Hodgkin's disease, embryonal tumours, neuroblastomas, nephtoblastomas, teratomas, adamantinomas, retroblastomas , haemangiomas, chordomas, odontomas, craniophacyngomas, hamartomas, lymphoangiomas, exostoses, neurofibrantos
- Administration of the compounds of the invention, or their pharmaceutically acceptable salts, in pure form or in an appropriate pharmaceutical composition can e.g. further be carried out via any of the accepted modes of administration or agents for serving similar utilities.
- administration can be, for example, orally, nasally, parenterally (intravenous, intramuscular, or subcutaneous) , topically, transdermalIy, intravaginally, intravesically, intracistemally, or rectally, in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms, such, as for example, tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, or the like, preferably in unit dosage forms suitable for simple administration of precise dosages.
- compositions will e.g. include a conventional pharmaceutical carrier or excipient and a compound of the invention as the/an active agent, and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, etc.
- Compositions of the invention may be used in combination with anticancer or other agents that are generally administered to a patient being treated for cancer.
- Adjuvants include e.g. preserving, wetting, suspending, sweetening, flavoring, perfuming, emulsifying, and dispensing agents.
- Prevention of the action of microorganisms can e.g. be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol , phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.
- a pharmaceutical composition of the invention may also contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, antioxidants, and the like, such as, for example, citric acid, sorbitan monolaurate, triethanolamine oleate, butylalted hydroxytoluene , etc.
- auxiliary substances such as wetting or emulsifying agents, pH buffering agents, antioxidants, and the like, such as, for example, citric acid, sorbitan monolaurate, triethanolamine oleate, butylalted hydroxytoluene , etc.
- compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
- suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propyleneglycol , polyethyleneglycol , glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate.
- Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
- One preferable route of administration is oral, using a convenient daily dosage regimen that can be adjusted according to the degree of severity of the disease-state to be treated.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
- the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or
- fillers or extenders as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid
- binders as for example, cellulose derivatives, starch, alignates, gelatin, polyvinylpyrrolidone, sucrose, and gum acacia
- humectants as for example, glycerol
- disintegrating agents as for example, agar- agar, calcium carbonate, potato or tapioca starch, alginic acid, croscarmellose sodium, complex silicates, and sodium carbonate
- solution retarders as for example paraffin
- absorption accelerators as for example, quatern
- Solid dosage forms as described above can be prepared with coatings and shells, such as enteric coatings and others well known in the art. They may contain pacifying agents, and can also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedded compositions that can be used are polymeric substances and waxes . The active compounds can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients .
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. Such dosage forms are prepared, for example, by dissolving, dispersing, etc., a compound(s) of the invention, or a pharmaceutically acceptable salt thereof, and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol and the like; solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol , 1 , 3-butyleneglycol, dimethylformamide; oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol, tetrahydrofurfuryl alcohol,
- Suspensions in addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.
- suspending agents as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.
- compositions for rectal administrations are, for example, suppositories that can be prepared by mixing the compounds of the present invention with for example suitable non- irritating excipients or carriers such as cocoa butter, polyethyleneglycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt while in a suitable body cavity and release the active component therein.
- suitable non- irritating excipients or carriers such as cocoa butter, polyethyleneglycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt while in a suitable body cavity and release the active component therein.
- Dosage forms for topical administration of a compound of this invention include ointments, powders, sprays, and inhalants.
- the active component is admixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants as may be required.
- Ophthalmic formulations, eye ointments, powders, and solutions are also contemplated as being within the scope of this invention.
- the pharmaceutically acceptable compositions will contain about 1% to about 99% by weight of a compound (s) of the invention, or a pharmaceutically acceptable salt thereof, and 99% to 1% by weight of a suitable pharmaceutical excipient.
- the composition will be between about 5% and about 75% by weight of a compound (s) of the invention, or a pharmaceutically acceptable salt thereof, with the rest being suitable pharmaceutical excipients.
- composition to be administered will, in any event, contain a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, for treatment of a disease-state in accordance with the teachings of this invention.
- the compounds of the invention are administered in a therapeutically effective amount which will vary depending upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of the compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular disease-states, and the host undergoing therapy.
- the compounds of the present invention can e.g. be administered to a patient at dosage levels in the range of about 0.1 to about 1,000 mg per day. For a normal human adult having a body weight of about 70 kilograms, a dosage in the range of about 0.01 to about 100 mg per kilogram of body weight per day is an example.
- the specific dosage used can vary.
- the dosage can depend on a number of factors including the requirements of the patient, the severity of the condition being treated, and the pharmacological activity of the compound being used.
- the determination of optimum dosages for a particular patient is well known to one of ordinary skill in the art .
- Scheme 1 depicts a general synthetic route for the preparation of compounds of the present invention and is not intended to be limiting.
- the reaction may be carried out as a multi component reaction, using reaction conditions that are favorable for product formation:
- the pentafluorphenyl esters from Example 2 were solved in THF and reacted with the corresponding amines during 1 hour at room temperature.
- the crude product was evaporated to dryness and the final purification was performed by column chromatography on silica with ethyl acetate / methanol mixtures as eluent .
- the pyrazolo [3 , 4-e] [1 , 4] thiazepines of Formula (I) were dissolved in acetic acid and treated with hydrogenperoxide during 1 hour at room temperature.
- the crude product was evaporated to dryness and the final purification was performed by column chromatography on silica with ethyl acetate / methanol mixtures as eluent .
- kinase assays were performed according to literature methods (e.g. as disclosed in Curtin, Cell Notes 2005, 13, 11- 15) known to an expert skilled in the art by using ⁇ 33 P ATP. The ATP concentrations were selected to be close to the Michaelis-Menten constant for each specific kinase. Dose- response experiments to determine IC 50 inhibition constants are performed by using different inhibitor concentrations in a 96- well plate format. Thus, a radiometric protein kinase was used for measuring the kinase activity of c-Met kinase.
- kinase assays were performed in 96 -well FlashPlates from Perkin Elmer (Boston, MA, USA) in a 50 ⁇ l reaction volume.
- the reaction cocktail was pipetted in 4 steps in the following order: 20 ⁇ l of assay buffer, 5 ⁇ l of ATP solution (in H 2 O) , 5 ⁇ l of test compound (in 10 % DMSO) , 10 ⁇ l of substrate / 10 ⁇ l of enzyme solution (premixed) .
- the assay contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl 2 , 3 mM MnCl 2 , 3 ⁇ M Na-orthovanadate, 1.2 mM DTT, 50 ⁇ g/ml PEG20000, 1 ⁇ M [ ⁇ -33P] -ATP (approx. 1.5 x 1005 cpm per well) .
- enzyme 100 ng/50 ⁇ l per well
- substrate poly(Ala, GIu, Lys, Tyr) 6:2:5:1 125 ng/50 ⁇ l were used per well.
- the reaction cocktails were incubated at 30° C for 80 minutes.
- Compounds of the present invention show a kinase inhibitory activity of below 100 ⁇ M in the described assay.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides compounds (pyrazolothiazepines) of formula (I) that inhibit or modulate the enzymatic activity of protein kinases.
Description
Novel compounds which modulate kinase activity
The present invention provides compounds that inhibit or modulate the enzymatic activity of protein kinases for modulating cellular activities such as proliferation, differentiation, programmed cell death, and migration. In particular, the invention provides novel compounds (e.g. pyrazolothiazepines) which inhibit, regulate and/or modulate kinase related signal transduction pathways resulting in changes of cellular activities, compositions which contain these compounds, and methods of using them to treat diseases and conditions that are related to kinase activities. The present invention also provides methods for the preparation of these compounds, and compositions containing these compounds.
New agents used to treat cancer are of considerable interest because a large variety of these neoplastic diseases have only poor and insufficient treatments. Improvements in the treatment of cancer are associated with identification of therapeutic agents acting through novel mechanisms, modulating cell signaling pathways.
Protein kinases catalyze protein phosphorylation. The consequences of this activity are for example cell differentiation and proliferation - cell function depends greatly on protein kinase activity. Furthermore, abnormal protein kinase activity has been related to a range of disorders, ranging from relatively non-life threatening diseases such as psoriasis to extremely life threatening diseases such as brain cancer.
About 20 different subfamilies of receptor-type tyrosine kinases have been identified, for example the HER subfamily,
the insulin subfamily, the PDGF subfamily and the FLK family. The PDGF and FLK families are usually considered as very similar.
The non-receptor type of tyrosine kinases comprises numerous subfamilies, including AbI, Src, Frk, Btk, Csk, Zap70, Fak, Jak, Ack, and LIMK. Each of these subfamilies contains a variety of kinases, for the Src subfamily includes Src, Yes, Fyn, Lyn, Lck, BIk, Hck, Fgr, Yrk known to promote oncogenesis .
Deregulation of protein kinase enzymatic activity through overexpression, mutation and other pathways may lead to undesired cellular properties, such as proliferation, differentiation, programmed cell death, and migration. Altered kinase signaling is also included in immunological disorders, cardiovascular diseases, inflammatory diseases, and degenerative diseases.
Therefore, protein kinases are attractive drug targets for small molecule drug discovery and several kinase inhibitors are effective therapeutics. For example, as demonstrated successfully with the approval of the c-Kit and AbI kinase inhibitor Gleevec for the treatment of Chronic Myeloid Leukemia (CML) and gastrointestinal stroma cancers (GIST) .
Inhibition or modulation of cell proliferation and angiogenesis, two key cellular processes needed for tumor growth and survival, is an attractive goal for development of small -molecule drugs - antiproliferative agents are desirable to slow or stop the growth of tumors. In addition, antiangiogenic therapy may represent an important approach for the treatment of solid tumors and other diseases associated
with overtly active vascularization, such as but not limited to ischemic coronary' artery disease, diabetic retinopathy, psoriasis and rheumatoid arthritis.
Thus, kinases are biological targets for small -molecule modulation of angiogenic and proliferative activity, such as for example the receptor kinase c-Met. c-Met occurs in a wide variety of. cell types including epithelial, endothelial and mesenchymal cells inducing cell migration, invasion, proliferation and other biological activities associated with invasive cell growth. The hepatocyte growth factor (HGF), "scatter factor" (SF) , as the endogenous ligand for c-Met is a potent inducer of angiogenesis and tumor growth. Anti-HGF antibodies or HGF antagonists and gene therapy have been shown to inhibit tumor metastasis in vivo (Matsumoto and Nakamura Cancer Science 2003, 94, 321-327) .
Another attractive target for small-molecule modulation is c- Kit . c-Kit is expressed in mast cells, immature myeloid cells, melanocytes, epithelial breast cells and the interstitial cells. In mast cells, it is required for differentiation, maturation, chemotaxis, and for the promotion of survival and proliferation.
Flt-3 is a kinase that is constitutively activated via mutation in a large proportion of acute myeloid leukemia (AML) patients and correlated with poor prognosis in AML patients (Sawyers Cancer Cell 2002, 1, 413-415) .
Therefore, small -molecule compounds that specifically inhibit, regulate and/or modulate the signal transduction of kinases, including c-Met, KDR, c-Kit, Flt-3, and Flt-4, and others are desirable as agents to treat or prevent disease states
associated with abnormal cell signaling through those kinases. Particularly interesting are those kinase inhibitors that exhibit a therapeutically useful inhibition profile and specificity against a range of kinases (Goldstein et al . Nature Reviews Drug Discovery 2008, 7, 391-397) .
Many chemical compounds, belonging to particular scaffolds have already been described as kinase inhibitors (Ghose et al . Journal Medicinal Chemistry 2008, 51, September 11) - however, especially desired are novel scaffolds that permit to achieve desired specificity, low toxicity and other therapeutically useful properties that allow the application of such compounds as therapeutically useful agents.
SUMMARY OF THE INVENTION
In one aspect, the present invention provides one or more compounds for modulating kinase activity and one or more methods of treating and/or preventing one or more diseases mediated by kinase activity utilizing the compound (s) and pharmaceutical composition (s) thereof. Diseases mediated by kinase activity include, but are not limited to, diseases characterized in part by cell migration, invasion, proliferation and other biological activities associated with invasive cell growth. In particular this invention relates to modulation, especially inhibition, of c-Met, KDR, c-Kit, flt- 3, and flt-4.
In another aspect, the invention also provides one or more pharmaceutical formulations comprising one or more compounds and/or pharmaceutical compositions of the present invention, as described herein. Such pharmaceutical formulations can also include one or more other compounds or compositions (for
example diluents, permeation enhancers, lubricants, and the like) .
In yet another aspect, the present invention provides a process for making a compound, and pharmaceutical composition thereof, for modulating kinase activity and treating diseases mediated by kinase activity. In particular this invention also relates to a method for making a pyrazolo [3 , 4- e] [1 , 4] thiazepine used for modulation of kinase activity, even more particular inhibition of kinase activity, and yet even more particular inhibition of c-Met, KDR, c-Kit, flt-3, and flt-4.
The composition of the invention is used to treat one or more diseases related to abnormal cellular activities. Diseases which can be treated by the methods and compositions provided herein include, but are not limited to, various forms of neoplastic diseases, immunological disorders such as rheumatoid arthritis, graft-host diseases, multiple sclerosis, psoriasis; cardiovascular diseases such as artheroscrosis, myocardioinfarction, ischemia, stroke and restenosis; other inflammatory and degenerative diseases such as interbowel diseases, macular degeneration and diabetic retinopathy.
It is appreciated that in some disease cases the cells may exhibit abnormal cellular activities and still require treatment. For example, during wound healing, cells may be proliferating "normally", but proliferation and migration enhancement may be desired. Alternatively, reduction in "normal" cell proliferation and/or migration rate may be desired.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides one or more compounds of formula (I)
(D wherein
X is S, SO or SO2;
R1 is a hydrogen atom or an alkyl, alkenyl, alkynyl, hetero- alkyl, aryl , heteroaryl, cycloalkyl, alkylcycloalkyl , heteroalkylcycloalkyl , heterocycloalkyl , aralkyl or hetero- aralkyl radical;
R2 is a hydrogen atom or an alkyl, alkenyl, alkynyl, hetero- alkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl , heteroalkylcycloalkyl, heterocycloalkyl, aralkyl or hetero- aralkyl radical;
R3 is a hydrogen atom or an alkyl, alkenyl, alkynyl, hetero- alkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl or hetero- aralkyl radical;
R4 is a hydrogen atom or an alkyl, alkenyl, alkynyl, hetero- alkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl or hetero- aralkyl radical; and
R5 is a hydrogen atom or an alkyl, alkenyl , alkynyl, hetero- alkyl, aryl , heteroaryl , cycloalkyl, alkylcycloalkyl , heteroalkylcycloalkyl, heterocycloalkyl , aralkyl or heteroaralkyl radical;
wherein all of the above radicals may be substituted;
or a pharmaceutically acceptable salt, ester, prodrug, solvate or hydrate or a pharmaceutically acceptable formulation thereof .
The expression alkyl refers to a saturated, straight-chain or branched hydrocarbon group that contains from 1 to 20 carbon atoms, preferably from 1 to 12 carbon atoms, especially from 1 to 6 (e.g. 1, 2, 3 or 4) carbon atoms, for example a methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert -butyl, n-pentyl, iso-pentyl, n-hexyl, 2 , 2-dimethylbutyl or n-octyl group.
The expressions alkenyl and alkynyl refer to at least partially unsaturated, straight-chain or branched hydrocarbon groups that contain from 2 to 20 carbon atoms, preferably from 2 to 12 carbon atoms, especially from 2 to 6 (e.g. 2, 3 or 4) carbon atoms, for example an ethenyl (vinyl) , propenyl
(allyl) , iso-propenyl , butenyl , ethinyl, propinyl, butinyl, acetylenyl, propargyl , isoprenyl or hex-2-enyl group. Preferably, alkenyl groups have one or two (especially preferably one) double bond(s) , and alkynyl groups have one or two
(especially preferably one) triple bond(s) .
Furthermore, the terms alkyl, alkenyl and alkynyl refer to groups in which one or more hydrogen atoms have been replaced
e.g. by a halogen atom (preferably F or Cl) such as, for example, a 2 , 2 , 2-trichloroethyl or a trifluoromethyl group.
The expression heteroalkyl refers to an alkyl , alkenyl or alkynyl group in which one or more (preferably 1, 2 or 3) carbon atoms, each independently, have been replaced by an oxygen, nitrogen, phosphorus, boron, selenium, silicon or sulfur atom (preferably by an oxygen, sulfur or nitrogen atom) . The expression heteroalkyl furthermore refers to a carboxylic acid or to a group derived from a carboxylic acid, such as, for example, acyl , acylalkyl, alkoxycarbonyl , acyloxy, acyloxyalkyl , carboxyalkylamide or alkoxycarbonyloxy.
Preferably, a heteroalkyl group contains from 1 to 12 carbon atoms and from 1 to 4 hetero atoms selected from oxygen, nitrogen and sulphur (especially oxygen and nitrogen) . Especially preferably, a heteroalkyl group contains from 1 to 6 (e.g. 1, 2, 3 or 4) carbon atoms and 1, 2 or 3 (especially 1 or 2) hetero atoms selected from oxygen, nitrogen and sulphur (especially oxygen and nitrogen) .
Examples of heteroalkyl groups are groups of formulae: Ra-O-Ya-, Ra-S-Ya-, Ra-N(Rb) -Ya-, Ra-CO-Ya-, Ra-O-CO-Ya-, Ra-CO-O-Ya-, Ra-CO-N(Rb) -Ya- , Ra-N (Rb) -CO-Ya- , Ra-O-CO-N (Rb) -Ya- , Ra-N (Rb) -CO-O-Ya- , Ra-N (Rb) -CO-N (Rc) -Ya- , Ra-0-CO-O-Ya- , Ra-N(Rb) -C(=NRd) -N(RC) -Ya-, Ra-CS-Ya-, Ra-O-CS-Ya-, Ra-CS-O-Ya-, Ra-CS-N(Rb) -Ya-, Ra-N(Rb) -CS-Ya-, Ra-O-CS-N (Rb) -Ya- , Ra-N(Rb) -CS-O-Ya-, Ra-N(Rb) -CS-N(RC) -Ya- , Ra-O-CS-O-Ya- , Ra-S-CO-Ya-, Ra-CO-S-Ya-, Ra-S-CO-N(Rb) -Ya-, Ra-N (Rb) -CO-S-Ya- , Ra-S-CO-O-Ya-, Ra-O-CO-S-Ya-, Ra-S-CO-S-Ya- , Ra-S-CS-Ya-, Ra-CS-S-Ya-, Ra-S-CS-N(Rb) -Ya- , Ra-N (Rb) -CS-S-Y3- , Ra-S-CS-O-Ya- , Ra-O-CS-S-Ya-, wherein Ra being a hydrogen atom, a C1-C6 alkyl, a C2 -C6 alkenyl or a C2-C6 alkynyl group; Rb being a hydrogen
atom, a Ci-C6 alkyl , a C2-C6 alkenyl or a C2-C6 alkynyl group; Rc being a hydrogen atom, a C1-C6 alkyl, a C2-C6 alkenyl or a C2-C6 alkynyl group; Rd being a hydrogen atom, a Ci-C6 alkyl, a C2-C6 alkenyl or a C2-C6 alkynyl group and Ya being a direct bond, a Ci-C6 alkylene, a C2-C6 alkenylene or a C2-C6 alkynylene group, wherein each heteroalkyl group contains at least one carbon atom and one or more hydrogen atoms may be replaced by fluorine or chlorine atoms.
Specific examples of heteroalkyl groups are methoxy, trifluoromethoxy, ethoxy, n-propyloxy, isopropyloxy, butoxy, tert-butyloxy, methoxymethyl , ethoxymethyl , -CH2CH2OH, -CH2OH, methoxyethyl , 1-methoxyethyl , 1-ethoxyethyl , 2 -methoxyethyl or 2-ethoxyethyl, methylamino, ethylamino, propylamino, isopropylamino, dimethylamino, diethylamino, isopropyl- ethylamino, methylamino methyl, ethylamino methyl, diiso- propylamino ethyl, methylthio, ethylthio, isopropylthio, enol ether, dimethylamino methyl, dimethylamino ethyl, acetyl, propionyl, butyryloxy, acetyloxy, methoxycarbonyl , ethoxy- carbonyl, propionyloxy, acetylamino or propionylamino, carboxymethyl , carboxyethyl or carboxypropyl , N-ethyl-N- methylcarbamoyl or N-methylcarbamoyl . Further examples of heteroalkyl groups are nitrile, isonitrile, cyanate, thio- cyanate, isocyanate, isothiocyanate and alkylnitrile groups.
The expression cycloalkyl refers to a saturated or partially unsaturated (for example, a cycloalkenyl group) cyclic group that contains one or more rings (preferably 1 or 2), and contains from 3 to 14 ring carbon atoms, preferably from 3 to 10 (especially 3, 4, 5, 6 or 7) ring carbon atoms. The expression cycloalkyl refers furthermore to groups in which one or more hydrogen atoms have been replaced by fluorine, chlorine, bromine or iodine atoms or by OH, =0, SH, =S, NH2,
=NH, N3 or NO2 groups, thus, for example, cyclic ketones such as, for example, cyclohexanone, 2-cyclohexenone or cyclopenta- none . Further specific examples of cycloalkyl groups are a cyclopropyl, cyclobutyl, cyclopentyl, spiro [4 , 5] decanyl , norbornyl , cyclohexyl, cyclopentenyl , cyclohexadienyl , decalinyl, bicyclo [4.3.0] nonyl , tetraline, cyclopentylcyclohexyl , fluorocyclohexyl or cyclohex-2-enyl group .
The expression heterocycloalkyl refers to a cycloalkyl group as defined above in which one or more (preferably 1, 2 or 3) ring carbon atoms, each independently, have been replaced by an oxygen, nitrogen, silicon, selenium, phosphorus or sulfur atom (preferably by an oxygen, sulfur or nitrogen atom) . A heterocycloalkyl group has preferably 1 or 2 ring(s) containing from 3 to 10 (especially 3, 4, 5, 6 or 7) ring atoms (preferably secected from C, 0, N and S) . The expression heterocycloalkyl refers furthermore to groups in which one or more hydrogen atoms have been replaced by fluorine, chlorine, bromine or iodine atoms or by OH, =0, SH, =S, NH2, =NH, N3 or NO2 groups. Examples are a piperidyl, prolinyl, imidazolidinyl , piperazinyl, morpholinyl, urotropinyl, pyrrolidinyl , tetra- hydrothiophenyl, tetrahydropyranyl , tetrahydrofuryl or 2-pyrazolinyl group and also lactames, lactones, cyclic imides and cyclic anhydrides.
The expression alkylcycloalkyl refers to a group that contains both cycloalkyl and also alkyl, alkenyl or alkynyl groups in accordance with the above definitions, for example alkylcycloalkyl, cycloalkylalkyl , alkylcycloalkenyl , alkenylcycloalkyl and alkynylcycloalkyl groups. An alkylcycloalkyl group preferably contains a cycloalkyl group that contains one or two ring systems having from 3 to 10 (especially 3, 4, 5, 6 or
7) ring carbon atoms, and one or two alkyl, alkenyl or alkynyl groups having 1 or 2 to 6 carbon atoms .
The expression heteroalkylcycloalkyl refers to alkylcycloalkyl groups as defined above in which one or more (preferably 1, 2 or 3) carbon atoms, each independently, have been replaced by an oxygen, nitrogen, silicon, selenium, phosphorus or sulfur atom (preferably by an oxygen, sulfur or nitrogen atom) . A heteroalkylcycloalkyl group preferably contains 1 or 2 ring systems having from 3 to 10 (especially 3, 4, 5, 6 or 7) ring atoms, and one or two alkyl, alkenyl, alkynyl or heteroalkyl groups having from 1 or 2 to 6 carbon atoms. Examples of such groups are alkylheterocycloalkyl , alkylheterocycloalkenyl , alkenylheterocycloalkyl , alkynylheterocycloalkyl , heteroalkylcycloalkyl, heteroalkylheterocycloalkyl and hetero- alkylheterocycloalkenyl, the cyclic groups being saturated or mono-, di- or tri -unsaturated.
The expression aryl or Ar refers to an aromatic group that contains one or more rings containing from 6 to 14 ring carbon atoms, preferably from 6 to 10 (especially 6) ring carbon atoms. The expression aryl (or Ar, respectively) refers furthermore to groups in which one or more hydrogen atoms have been replaced by fluorine, chlorine, bromine or iodine atoms or by OH, SH, NH2, N3 or NO2 groups. Examples are the phenyl, naphthyl , biphenyl , 2-fluorophenyl , anilinyl, 3 -nitrophenyl or 4 -hydroxyphenyl group .
The expression heteroaryl refers to an aromatic group that contains one or more rings containing from 5 to 14 ring atoms, preferably from 5 to 10 (especially 5 or 6) ring atoms, and contains one or more (preferably 1, 2, 3 or 4) oxygen, nitrogen, phosphorus or sulfur ring atoms (preferably 0, S or
N) . The expression heteroaryl refers furthermore to groups in which one or more hydrogen atoms have been replaced by fluorine, chlorine, bromine or iodine atoms or by OH, SH, N3, NH2 or NO2 groups. Examples are pyridyl (e.g. 4-pyridyl) , imidazolyl (e.g. 2-imidazolyl) , phenylpyrrolyl (e.g. 3- phenylpyrrolyl) , thiazolyl, isothiazolyl , 1 , 2 , 3-triazolyl , 1 , 2 , 4-triazolyl , oxadiazolyl , thiadiazolyl , indolyl , indazolyl, tetrazolyl, pyrazinyl, pyrimidinyl , pyridazinyl, oxazolyl , isoxazolyl, triazolyl, tetrazolyl, isoxazolyl, indazolyl, indolyl, benzimidazolyl , benzoxazolyl , benzisoxazolyl , benzthiazolyl , pyridazinyl, quinolinyl, isoquinolinyl , pyrrolyl, purinyl , carbazolyl, acridinyl , pyrimidyl, 2,3'- bifuryl, pyrazolyl (e.g. 3-pyrazolyl) and isoquinolinyl groups .
The expression aralkyl refers to a group containing both aryl and also alkyl, alkenyl, alkynyl and/or cycloalkyl groups in accordance with the above definitions, such as, for example, an arylalkyl, arylalkenyl , arylalkynyl, aryleye1oalkyl , aryl- cycloalkenyl , alkylarylcycloalkyl and alkylarylcycloalkenyl group. Specific examples of aralkyls are toluene, xylene, mesitylene, styrene, benzyl chloride, o-fluorotoluene, lH-indene, tetraline, dihydronaphthalene, indanone, phenylcyclopentyl , cumene, cyclohexylphenyl , fluorene and indane. An aralkyl group preferably contains one or two aromatic ring systems (1 or 2 rings) containing from 6 to 10 carbon atoms and one or two alkyl , alkenyl and/or alkynyl groups containing from 1 or 2 to 6 carbon atoms and/or a cycloalkyl group containing 5 or 6 ring carbon atoms .
The expression heteroaralkyl refers to an aralkyl group as defined above in which one or more (preferably 1, 2, 3 or 4) carbon atoms, each independently, have been replaced by an
oxygen, nitrogen, silicon, selenium, phosphorus, boron or sulfur atom (preferably oxygen, sulfur or nitrogen) , that is to say to a group containing both aryl or heteroaryl, respectively, and also alkyl, alkenyl, alkynyl and/or heteroalkyl and/or cycloalkyl and/or heterocycloalkyl groups in accordance with the above definitions. A heteroaralkyl group preferably contains one or two aromatic ring systems (1 or 2 rings) containing from 5 or 6 to 10 ring carbon atoms and one or two alkyl, alkenyl and/or alkynyl groups containing 1 or 2 to 6 carbon atoms and/or a cycloalkyl group containing 5 or 6 ring carbon atoms, wherein 1, 2, 3 or 4 of these carbon atoms have been replaced by oxygen, sulfur or nitrogen atoms.
Examples are arylheteroalkyl , arylheterocycloalkyl , aryl- heterocycloalkenyl , arylalkylheterocycloalkyl , arylalkenyl- heterocycloalkyl , arylalkynylheterocycloalkyl, arylalkyl- heterocycloalkenyl , heteroarylalkyl , heteroarylalkenyl , heteroarylalkynyl, heteroarylheteroalkyl , heteroaryl - cycloalkyl, heteroarylcycloalkenyl , heteroarylhetero- cycloalkyl, heteroarylheterocycloalkenyl , heteroarylalkyl - cycloalkyl, heteroarylalkylheterocycloalkenyl , heteroaryl - heteroalkylcycloalkyl , heteroarylheteroalkylcycloalkenyl and heteroarylheteroalkylheterocycloalkyl groups, the cyclic groups being saturated or mono-, di- or tri -unsaturated. Specific examples are a tetrahydroisoquinolinyl , benzoyl, 2- or 3-ethylindolyl, 4-methylpyridino, 2-, 3- or 4-methoxyphenyl , 4-ethoxyphenyl , 2-, 3- or 4-carboxy- phenylalkyl group.
As already stated above, the expressions cycloalkyl, heterocycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, aryl, heteroaryl, aralkyl and heteroaralkyl also refer to groups in which one or more hydrogen atoms of such groups have been
replaced by fluorine, chlorine, bromine or iodine atoms or by OH, =0, SH, =S, NH2, =NH, N3 or NO2 groups.
The expression "optionally substituted" refers to a group in which one, two, three or more hydrogen atoms have been replaced by fluorine, chlorine, bromine or iodine atoms or by OH, =0, SH, =S, NH2, =NH, N3 or NO2 groups. This expression refers furthermore to a group that are substituted by one, two, three or more (preferably unsubstituted) Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl , Ci-C6 heteroalkyl, C3-Ci0 cycloalkyl, C2-C9 heterocycloalkyl, C2-Ci2 alkylcycloalkyl , C2-Cn hetero- alkylcycloalkyl C6-Ci0 aryl , Ci-C9 heteroaryl, C7-Ci2 aralkyl or C2-Cn heteroaralkyl groups.
Preferably, all alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkylcycloalkyl , heteroalkylcycloalkyl, aralkyl and heteroaralkyl groups described herein may optionally be substituted.
Preferred are compounds of formula (I) wherein X is S or SO2, especially S.
Further preferred are compounds of formula (I) wherein R1 is an optionally substituted aryl or heteroaryl or an alkyl radical.
Moreover preferred are compounds of formula (I) wherein R1 is an optionally substituted phenyl radical or an optionally substituted heteroaryl radical containing 5 or 6 ring atoms and 1, 2, 3 or 4 heteroatoms selected from 0, S and N.
Especially preferred are compounds of formula (I) wherein R1 has the following structure
wherein the groups R6 are independently from each other a halogen atom or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl , heteroaryl , cycloalkyl, alkylcycloalkyl , heteroalkylcyclo- alkyl, heterocycloalkyl , aralkyl or heteroaralkyl radical and m is 0, 1, 2, 3, 4 or 5 (especially 0 or 1) .
Further preferred, R6 is F, Cl, Br, CN, NHCOMe, Me, OMe, CF3 or OCF3.
Further preferred are compounds of formula (I) wherein R2 is an optionally substituted aryl or heteroaryl radical .
Moreover preferred are compounds of formula (I) wherein R2 is an optionally substituted phenyl or naphthyl radical or an optionally substituted heteroaryl radical containing 5 or 6 to 10 ring atoms (i.e. one or two rings) and 1, 2, 3 or 4 heteroatoms selected from 0, S and N.
Especially preferred are compounds of formula (I) wherein R2 has the following structure
wherein the groups R7 are independently from each other a halogen atom or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcyclo- alkyl, heterocycloalkyl, aralkyl or heteroaralkyl radical and o is 0, 1, 2, 3, 4 or 5 (especially 0, 1 or 2) .
Further preferred, R7 is F, Cl, OMe, Me, SO2Me, NHCOMe, COOH, COOMe, OCH2COOMe, OCH2COOH, benzyl, a heterocycloalkyl (e.g. a
morpholinyl or a piperazinyl) radical, or an heteroalkylcycloalkyl (e.g. a -CH2 -morpholinyl, -CH2- piperazinyl, -CH2-N-Methylpiperazinyl or an N-methyl- piperazinyl) radical.
Moreover preferred are compounds of formula (I) wherein R3 is a hydrogen atom or Ci-C4 alkyl, especially hydrogen.
Further preferred are compounds of formula (I) wherein R4 is a hydrogen atom or an alkyl, heteroalkyl or a heteroalkylcycloalkyl radical .
Especially preferred are compounds of formula (I) wherein R4 is hydrogen, Ci-C4 alkyl or a group of formula CH2COR8 wherein R8 is hydroxy or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl , heteroaryl, cycloalkyl, alkylcycloalkyl , heteroalkylcycloalkyl, heterocycloalkyl , aralkyl or heteroaralkyl radical; especially preferably, R8 is hydroxy or NH (CH2) PR9, wherein p is 0, 1, 2, 3 or 4 and R9 is a heterocycloalkyl radical (preferably containing 5 or 6 ring atoms and 1, 2, 3 or 4 heteroatoms selected from 0, S and N) .
Further preferred are compounds of formula (I) wherein R5 is hydrogen .
Especially preferably, the compounds of formula (I) are selected from the following compounds:
• 3, 4-Diphenyl-2, 8-dihydro-4H-pyrazolo [3,4- e] [1, 4] thiazepin-7-one
• 5, 5-Dioxo-3 , 4-diphenyl-2, 5,6, 8-tetrahydro-4H-5lambda*6*- pyrazolo [3,4-e] [1,4] thiazepin-7-one
• (7-Oxo-3,4-diphenyl-2 ,6,7, 8-tetrahydro-4H-pyrazolo [3,4- e] [1, 4] thiazepin-6-yl) -acetic acid
• 3- (3-Morpholin-4-yl-phenyl) -4-phenyl-2 , 8-dihydro-4H- pyrazolo [3,4-e] [1,4] thiazepin-7-one
• 3- (3 -Morpholin-4-yl-phenyl) -5 , 5-dioxo-4-phenyl-2 ,5,6,8- tetrahydro-4H-5lambda*6*-pyrazolo [3 , 4-e] [1, 4] thiazepin-7- one
• [3- (3 -Morpholin-4-yl-phenyl) -7-oxo-4-phenyl-2 , 6,7,8- tetrahydro-4H-pyrazolo [3,4-e] [1,4] thiazepin-6-yl] -acetic acid
• 4- (4 -Morpholin-4-ylmethyl -phenyl) -3-phenyl-2 , 8-dihydro- 4H-pyrazolo [3,4-e] [1,4] thiazepin-7-one
• [4- (4 -Morpholin-4-ylmethyl -phenyl) -7-oxo-3-phenyl- 2,6,7, 8-tetrahydro-4H-pyrazolo [3,4-e] [1,4] thiazepin-6- yl] -acetic acid
• 4- [4- (4 -Methyl -piperazin-1-ylmethyl) -phenyl] -3-phenyl- 2, 8-dihydro-4H-pyrazolo [3,4-e] [1,4] thiazepin-7-one
• {4- [4- (4 -Methyl -piperazin-1-ylmethyl) -phenyl] -7-oxo-3- phenyl-2, 6,7, 8-tetrahydro-4H-pyrazolo [3,4- e] [1,4] thiazepin-6-yl} -acetic acid
• 6-Methyl-4- [4- (4-methyl-piperazin-l-ylmethyl) -phenyl] -3- phenyl-2 , 8-dihydro-4H-pyrazolo [3 , 4-e] [1,4] thiazepin-7-one
• 4- (4-Chloro-phenyl) -3-phenyl-2 , 8-dihydro-4H-pyrazolo [3,4- e] [1 , 4] thiazepin-7-one
• 4- (3 , 4 -Dimethoxy-phenyl) -3 -phenyl -2 , 8-dihydro-4H- pyrazolo [3,4-e] [1,4] thiazepin-7-one
• 4- (4 -Morpholin-4-yl-phenyl) -3-phenyl-2 , 8-dihydro-4H- pyrazolo [3,4-e] [1,4] thiazepin-7-one
• 4- (7-0x0-3 -phenyl -2 ,6,7, 8-tetrahydro-4H-pyrazolo [3,4- e] [1, 4] thiazepin-4-yl) -benzoic acid methyl ester
• 4- (lH-Indol-3-yl) -3-phenyl-2 , 8-dihydro-4H-pγrazolo [3,4- e] [1, 4] thiazepin-7-one
• [3- (4-Fluoro-phenyl) -4- (4 -morpholin-4-ylmethyl -phenyl) -7- oxo-2 ,6,7, 8-tetrahydro-4H-pyrazolo [3,4-e] [1,4] thiazepin- 6-yl] -acetic acid
• [3- (4-Chloro-phenyl) -4- (4 -morpholin-4-ylmethyl -phenyl) -7- oxo-2, 6,7, 8-tetrahydro-4H-pyrazolo [3,4-e] [1,4] thiazepin- 6-yl] -acetic acid
• N- (3-Morpholin-4-yl-propyl) -2- (7-oxo-3 , 4-diphenyl- 2,6,7, 8-tetrahydro-4H-pyrazolo [3,4-e] [1,4] thiazepin-6- yl) -acetamide
• [3- (4-Fluoro-phenyl) -7-oxo-4-phenyl-2 , 6,7, 8-tetrahydro- 4H-pyrazolo [3 , 4-e] [1 , 4] thiazepin-6-yl] -acetic acid
• [3- (4-Chloro-phenyl) -7-oxo-4-phenyl-2 ,6,7, 8-tetrahydro- 4H-pyrazolo [3 , 4-e] [1, 4] thiazepin-6-yl] -acetic acid
• 2- [3- (4-Fluoro-phenyl) -7-oxo-4-phenyl-2 , 6,7, 8-tetrahydro- 4H-pyrazolo [3,4-e] [1,4] thiazepin-6-yl] -N- (3 -morpholin-4- yl -propyl) -acetamide
• 2- [3- (4-Chloro-phenyl) -7-oxo-4-phenyl-2 , 6,7, 8-tetrahydro- 4H-pyrazolo [3,4-e] [1,4] thiazepin-6-yl] -N- (3-morpholin-4- yl -propyl) -acetamide
• 4- (6-Carboxymethyl-7-oxo-3-phenyl-2, 6,7, 8-tetrahydro-4H- pyrazolo [3 , 4-e] [1 , 4] thiazepin-4-yl) -benzoic acid methyl ester
• [4- (4-Methoxy-phenyl) -7-oxo-3-phenyl-2 , 6,7, 8-tetrahydro- 4H-pyrazolo [3 , 4-e] [1 , 4] thiazepin-6-yl] -acetic acid
• N- (2-Morpholin-4-yl-ethyl) -2- (7-oxo-3 , 4-diphenyl-2 ,6,7,8- tetrahydro-4H-pyrazolo [3,4-e] [1,4] thiazepin-6-yl) - acetamide
• N- (4-Morpholin-4-yl-butyl) -2- (7-oxo-3 , 4-diphenyl-2 ,6,7,8- tetrahydro-4H-pyrazolo [3 , 4-e] [1,4] thiazepin-6-yl) - acetamide
• N- [2- (4-Methyl-piperazin-l-yl) -ethyl] -2- (7-oxo-3,4- diphenyl-2, 6,7, 8-tetrahydro-4H-pyrazolo [3,4- e] [1, 4] thiazepin-6-yl) -acetamide
• 2- [3- (4-Fluoro-phenyl) -7-oxo-4-phenyl-2 , 6,7, 8-tetrahydro- 4H-pyrazolo [3,4-e] [1,4] thiazepin-6-yl] -N, N-dimethyl - acetamide
• 3 -Methyl -4 -phenyl -2 , 8-dihydro-4H-pyrazolo [3,4- e] [1, 4] thiazepin-7-one
• [4- (4 -Methanesulfonyl-phenyl) -7-oxo-3-phenyl-2 ,6,7,8- tetrahydro-4H-pyrazolo [3 , 4-e] [1,4] thiazepin-6-yl] -acetic acid
• [4- (4 -Acetylamino-phenyl) -7-oxo-3-phenyl-2 , 6,7,8- tetrahydro-4H-pyrazolo [3 , 4-e] [1,4] thiazepin-6-yl] -acetic acid
• [4- (4-Methoxycarbonylmethoxy-phenyl) -7-oxo-3-phenyl- 2,6,7, 8-tetrahydro-4H-pyrazolo [3,4-e] [1,4] thiazepin-6- yl] -acetic acid
• [4- (4-Benzyloxy-phenyl) -7-oxo-3-phenyl-2 , 6,7,8- tetrahydro-4H-pyrazolo [3,4-e] [1,4] thiazepin-6-yl] -acetic acid
• 4- {6- [ (2-Morpholin-4-yl-ethylcarbamoyl) -methyl] -7-oxo-3- phenyl-2 ,6,7, 8-tetrahydro-4H-pyrazolo [3,4- e] [1 , 4] thiazepin-4-yl} -benzoic acid methyl ester
• 2- [4- (4-Methoxy-phenyl) -7-oxo-3-phenyl-2 , 6,7,8- tetrahydro-4H-pyrazolo [3,4-e] [1,4] thiazepin-6-yl] -N- (2- morpholin-4-yl -ethyl) -acetamide
• 2- [4- (4-Benzyloxy-phenyl) -7-oxo-3-phenyl-2 , 6,7,8- tetrahydro-4H-pyrazolo [3,4-e] [1,4] thiazepin-6-yl] -N- (2- morpholin-4-yl -ethyl) -acetamide
• (3-Furan-2-yl-7-oxo-4-phenyl-2, 6,7, 8-tetrahydro-4H- pyrazolo [3, 4-e] [1 , 4] thiazepin-6-yl) -acetic acid
• 2- (3-Furan-2-yl-7-oxo-4-phenyl-2, 6,7, 8-tetrahydro-4H- pyrazolo [3, 4-e] [1, 4] thiazepin-6-yl) -N- (2-morpholin-4-yl- ethyl) -acetamide
• 6- [2- (4-Methyl-piperazin-l-yl) -2-oxo-ethyl] -3 , 4-diphenyl- 2, 8-dihydro-4H-pyrazolo [3,4-e] [1,4] thiazepin-7-one
• (3-Methyl-7-oxo-4-phenyl-2, 6,7, 8-tetrahydro-4H- pyrazolo [3 , 4-e] [1 , 4] thiazepin-6-yl) -acetic acid
• 2- (3 -Methyl -7-oxo-4-phenyl-2, 6,7, 8-tetrahydro-4H- pyrazolo [3,4-e] [1,4] thiazepin-6-yl) -N- (2-morpholin-4-yl- ethyl) -acetamide
• [4- (lH-Indol-3-yl) -7-oxo-3-phenyl-2 , 6,7, 8-tetrahydro-4H- pyrazolo [3 , 4-e] [1 , 4] thiazepin-6-yl] -acetic acid
• 2- [4- (lH-Indol-3-yl) -7-oxo-3-phenyl-2 , 6 , 7, 8-tetrahydro- 4H-pyrazolo [3,4-e] [1,4] thiazepin-6-yl] -N- (2-morpholin-4- yl -ethyl) -acetamide
• 2- [4- (4-Methanesulfonyl -phenyl) -7-oxo-3-phenyl-2 ,6,7,8- tetrahydro-4H-pyrazolo [3,4-e] [1,4] thiazepin-6-yl] -N- (2- morpholin-4-yl -ethyl) -acetamide
• 2- [4- (4-Acetylamino-phenyl) -7-oxo-3 -phenyl -2 , 6,7,8- tetrahydro-4H-pyrazolo [3,4-e] [1,4] thiazepin-6-yl] -N- (2- morpholin-4-yl -ethyl) -acetamide
• (4- {6- [ (2-Morpholin-4-yl-ethylcarbamoyl) -methyl] -7-oxo-3- phenyl-2 , 6,7, 8-tetrahydro-4H-pyrazolo [3,4- e] [1, 4] thiazepin-4-yl} -phenoxy) -acetic acid methyl ester
• 3 -Methyl -4- (4-morpholin-4-ylmethyl-phenyl) -2 , 8-dihydro- 4H-pyrazolo [3,4-e] [1,4] thiazepin-7-one
Further preferred, the compounds disclosed in the following documents are excluded from the present invention:
1. Abu Elmaati, Tarek M et al . "Routes to Pyrazolo [3 , 4- e] [1, 4] thiazepine, Pyrazolo [1 , 5 -a] pyrimidine and Pyrazole
Derivatives" Journal of the Chinese Chemical Society,
2003, vol. 50, no. 3A, 413-418. (especially compounds 3a and 3b)
US 3,891,630 (Swett) . (especially compounds of gerneral formula I of US 3,891,630 wherein W is NH and/or the compound of example 18)
Joshi Krishna C et al . "Possible psychopharmacological agents Part 3 : Synthesis and CNS Activity of Some New Fluorine-Containing Pyrazolo [3 , 4-e] [1 , 4] thiazepines" , PHARMAZIE, 1979, vol. 34, no. 11, 716-718. (especially compounds 4g and 4h)
Sofan, M A et al . "Reactions with heterocyclic amidines : Synthesis of pyrazolo [3 , 4-e] thiazepine, pyrazolo [1 , 5- c] 1 , 2 , 4-triazine and pyrazolo [1 , 5-a] pyrimidine derivatives", PHARMAZIE, 1994, vol. 49, no. 7, 482-486. (especially compounds 5a, 5b and 5d)
Further preferred, the following compounds are excluded from the present invention:
Further, the following compounds of formula (II) are excluded from the present invention:
(ID
wherein W is NH,
R is hydrogen, loweralkyl or phenyl,
R2 is loweralkyl, cyclopropyl, 2-furyl or
, wherein X is hydrogen, halogen, trifluoromethyl , hydroxy, loweralkoxy or dimethylamino and Y is hydrogen, chlorine or loweralkoxy, R3 is hydrogen or loweralkyl,
R4 is hydrogen, loweralkyl or carboxyloweralkyl , and R5 is hydrogen, loweralkyl or diloweralkylamino- loweralkyl ; wherein the term "loweralkyl" or "loweralkoxy" is intended to refer to saturated hydrocarbon chains of 1 - 7 carbon atoms .
In one aspect of the present invention, a compound of formula (I) is used to modulate kinase activity.
Another aspect of the invention is a metabolite of a compound of formula (I) or a pharmaceutical composition thereof.
Another aspect of the invention is a pharmaceutical composition comprising a compound of Formula (I) and a pharmaceutically acceptable carrier.
The present invention further relates to a method of modulating the in vivo activity of a kinase, by administering to a mammal an effective amount of the compound of Formula (I) or the pharmaceutical composition containing a compound of Formula (I) .
Another aspect of the present invention relates to a method, wherein modulating the in vivo activity of a kinase comprises inhibition of said kinase.
Another aspect of the invention is a method of modulating the in vivo activity of a kinase, the method comprising administering to a subject an effective amount of the compound or the pharmaceutical composition described herein, wherein preferentially modulating the in vivo activity of the kinase comprises inhibition of said kinase, more preferentially wherein the kinase is at least one of c-Met, KDR, c-Kit, flt- 3, and flt-4.
Another aspect of the invention is a method of treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of the compound or the pharmaceutical composition as described.
The present invention further relates to a method of inhibiting proliferative activity in a cell, the method comprising administering an effective amount of a compound of Formula (I) to a cell or a plurality of cells.
The present invention further relates to a method of treating mammalian diseases or disorders associated with abnormal and unwanted cellular activities, the method comprising administering to a mammal a therapeutically effective amount of one or more compounds of Formula (I) .
The present invention further relates to a process for preparing a compound of Formula (I) , wherein an aminopyrazole, an aldehyde and a thioacetic acid derivative are reacted together, optionally in the presence of a base, optionally with heating or microwave radiation, to form compounds of Formula (I) .
The present invention further relates to a process for preparing a compound of Formula (I), wherein a compound of
Formula (I) is reacted with further compounds to form derivatives of Formula (I) .
The term metabolite refers to a product of a compound of Formula (I) produced by metabolism or biotransformation in the animal or human body; for example, biotransformation to a more polar molecule such as by oxidation, reduction, or hydrolysis, or to a conjugate (see Goodman and Gilman, "The Pharmacological Basis of Therapeutics" 8 th Ed., Pergamon Press, Gilman et al . , (eds) , 1990) . As used herein, the metabolite of a compound of the invention or its salt may be the biologically active form of the compound in the body. In
one example, a prodrug may be used such that the biologically active form, a metabolite, is released in vivo. Such metabolites are also encompassed within the scope of the present invention.
Examples of pharmacologically acceptable salts of sufficiently basic compounds of formula (I) are salts of physiologically acceptable mineral acids like hydrochloric, hydrobromic, sulfuric and phosphoric acid; or salts of organic acids like methanesulfonic, p-toluenesulfonic, lactic, acetic, trifluoroacetic, citric, succinic, fumaric, maleic and salicylic acid. Further, a sufficiently acidic compound of formula (I) may form alkali or earth alkaline metal salts, for example sodium, potassium, lithium, calcium or magnesium salts; ammonium salts; or organic base salts, for example methylamine, dimethylamine, trimethylamine, triethylamine, ethylenediamine, ethanolamine, choline hydroxide, meglumin, piperidine, morpholine, tris- (2 -hydroxyethyl) amine, lysine or arginine salts; all of which are also further examples of salts of formula (I) . Compounds of formula (I) may be solvated, especially hydrated. The hydratization/hydration may occur during the process of production or as a consequence of the hygroscopic nature of the initially water free compounds of formula (I) . The solvates and/or hydrates may e.g. be present in solid or liquid form.
It should be appreciated that certain compounds of formula (I) may have tautomeric forms from which only one might be specifically mentioned or depicted in the following description, different geometrical isomers (which are usually denoted as cis/trans isomers or more generally as (E) and (Z) isomers) or different optical isomers as a result of one or more chiral carbon atoms (which are usually nomenclatured
under the Cahn-Ingold-Prelog or R/S system) . All these tautomeric forms, geometrical or optical isomers (as well as racemates and diastereomers) and polymorphous forms are included in the invention. Since the compounds of formula (I) may contain asymmetric C-atoms, they may be present either as achiral compounds, mixtures of diastereomers, mixtures of enantiomers or as optically pure compounds. The present invention comprises both all pure enantiomers and all pure diastereomers, and also the mixtures thereof in any mixing ratio .
E.g. compounds of formula (I) may have imino, amino, oxo or hydroxy substituents off aromatic heterocyclic systems. For purposes of this disclosure, it is understood that such imino, amino, oxo or hydroxy substituents may exist in their corresponding tautomeric form, i.e., as amino, imino, hydroxy or oxo, respectively.
The therapeutic use of compounds according to formula (I) , their pharmacologically acceptable salts, solvates and hydrates, respectively, as well as formulations and pharmaceutical compositions also lie within the scope of the present invention.
The pharmaceutical compositions according to the present invention comprise at least one compound of formula (I) as an active ingredient and, optionally, carrier substances and/or adjuvants .
The present invention also relates to pro-drugs which are composed of a compound of formula (I) and at least one pharmacologically acceptable protective group which will be cleaved off under physiological conditions, such as an
alkoxy-, arylalkyloxy- , acyl-, acyloxymethyl group (e.g. pivaloyloxymethyl) , an 2-alkyl-, 2-aryl- or 2-arylalkyl- oxycarbonyl-2-alkylidene ethyl group or an acyloxy group as defined herein, e.g. ethoxy, benzyloxy, acetyl or acetyloxy or, especially for a compound of formula (I) , carrying a hydroxy group (-OH) : a sulfate, a phosphate (-OPO3 or OCH2OPO3) or an ester of an amino acid. Especially preferred are pro-drugs of the hydroxy group of a compound of formula (I) .
As mentioned above, therapeutically useful agents that contain compounds of formula (I) , their solvates, salts or formulations are also comprised in the scope of the present invention. In general, compounds of formula (I) will be administered by using the known and acceptable modes known in the art, either alone or in combination with any other therapeutic agent.
For oral administration such therapeutically useful agents can be administered by one of the following routes: oral, e.g. as tablets, dragees, coated tablets, pills, semisolids, soft or hard capsules, for example soft and hard gelatine capsules, aqueous or oily solutions, emulsions, suspensions or syrups, parenteral including intravenous, intramuscular and subcutaneous injection, e.g. as an injectable solution or suspension, rectal as suppositories, by inhalation or insufflation, e.g. as a powder formulation, as microcrystals or as a spray (e.g. liquid aerosol), transdermal, for example via an transdermal delivery system (TDS) such as a plaster containing the active ingredient or intranasal . For the production of such tablets, pills, semisolids, coated tablets, dragees and hard, e.g. gelatine, capsules the therapeutically useful product may be mixed with pharmaceutically inert,
inorganic or organic excipients as are e.g. lactose, sucrose, glucose, gelatine, malt, silica gel, starch or derivatives thereof, talc, stearinic acid or their salts, dried skim milk, and the like. For the production of soft capsules one may use excipients as are e.g. vegetable, petroleum, animal or synthetic oils, wax, fat, polyols. For the production of liquid solutions, emulsions or suspensions or syrups one may use as excipients e.g. water, alcohols, aqueous saline, aqueous dextrose, polyols, glycerin, lipids, phospholipids, cyclodextrins, vegetable, petroleum, animal or synthetic oils. Especially preferred are lipids and more preferred are phospholipids (preferred of natural origin; especially preferred with a particle size between 300 to 350 nm) preferred in phosphate buffered saline (pH = 7 to 8, preferred 7.4) . For suppositories one may use excipients as are e.g. vegetable, petroleum, animal or synthetic oils, wax, fat and polyols. For aerosol formulations one may use compressed gases suitable for this purpose, as are e.g. oxygen, nitrogen and carbon dioxide. The pharmaceutically useful agents may also contain additives for conservation, stabilization, e.g. UV stabilizers, emulsifiers, sweetener, aromatizers, salts to change the osmotic pressure, buffers, coating additives and antioxidants .
Compounds of formula (I) of the present invention may be used for the treatment and/or prevention of the following diseases:
Diseases associated with kinase activities including tumor growth (cancer) , pathologic neovascularization that supports solid tumor growth, and associated with other diseases where excessive local vascularization is involved such as ocular diseases (diabetic retinopathy, age-related macular
degeneration, and the like) and inflammation (psoriasis, rheumatoid arthritis, and the like) .
Furthermore, the present invention relates to the use of compounds of formula (I) for the preparation of medicaments for the treatment and/or prevention of the diseases described herein.
In general, in the case of oral or parenteral administration to adult humans weighing approximately 80 kg, a daily dosage of about 1 mg to about 10,000 mg, preferably from about 20 mg to about 1,000 mg, may e.g. be appropriate, although the upper limit may be exceeded when indicated. The daily dosage can be administered as a single dose or in divided doses, or for parenteral administration, it may be given as continuous infusion or subcutaneous injection.
A therapeutically effective amount of a compound in accordance with this invention means an amount of compound that is effective to prevent, alleviate or ameliorate symptoms of disease or prolongs the survival of the subject being treated. Determination of a therapeutically effective amount is within the skill in the art.
The therapeutically effective amount or dosage of a compound according to this invention can vary within wide limits and may be determined in a manner known in the art . Such dosage may be adjusted to the individual requirements in each particular case including the specific compound being administered, the route of administration, the condition being treated, as well as the patient being treated.
The term cancer as used herein refers to cellular- proliferative disease states, benign and malignant tumours that are solid or cystic in nature, adenomas, cystadenomas, papilloimas, adenocarcinonmas, adenocarcinonmas of the cirrhotic typo, basal cell carcinomas, sarcomas, fibrosarcomas, liposarcomas, lymphosarcomas, rhabdomyosarcomas, myxosarcomas, chondrosarcomas, reticulum cell sarcomas, Hodgkin's disease, embryonal tumours, neuroblastomas, nephtoblastomas, teratomas, adamantinomas, retroblastomas , haemangiomas, chordomas, odontomas, craniophacyngomas, hamartomas, lymphoangiomas, exostoses, neurofibrantosis, melanomas, lymphomas, hepatoblastomas, mammary carcinomas, cervical carcinomas, choriocarcinomas, adenoacanthomas, androblastomas, leiomyomas, arrhenoblastomas, Sertoli's cell tumours, theca and granulosa cell tumours, germinomas and seminomas, ovarian and vulvar carcinomas, urinary bladder and prostate carcinomas, tumours caused by schistosomiasis, astrocytomas, ependymogliomas, glioblastomas, medulloblastoma, oligodendrogliomas, spongioblastomas, meningeomas, tumours of Schwann's sheath cells, pinealomas, haemangioblastomas, osteoclastomas, Ewing ' s tumours, multiple myelomas, mycosis fungoides, Burkitt ' s tumours, leukaemias, acute and chronic lymphatic leukaemias, acute and chronic granulocytic leukaemias, acute and chronic monocytic leukaemias, stem cell leukaemias, basaliomas, fibromas, myomas, and metastases of any form of tumour that are accessible by surgical intervention in the form of a local injection.
Administration of the compounds of the invention, or their pharmaceutically acceptable salts, in pure form or in an appropriate pharmaceutical composition, can e.g. further be carried out via any of the accepted modes of administration or
agents for serving similar utilities. Thus, administration can be, for example, orally, nasally, parenterally (intravenous, intramuscular, or subcutaneous) , topically, transdermalIy, intravaginally, intravesically, intracistemally, or rectally, in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms, such, as for example, tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, or the like, preferably in unit dosage forms suitable for simple administration of precise dosages.
The compositions will e.g. include a conventional pharmaceutical carrier or excipient and a compound of the invention as the/an active agent, and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, etc. Compositions of the invention may be used in combination with anticancer or other agents that are generally administered to a patient being treated for cancer. Adjuvants include e.g. preserving, wetting, suspending, sweetening, flavoring, perfuming, emulsifying, and dispensing agents. Prevention of the action of microorganisms can e.g. be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol , phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.
If desired, a pharmaceutical composition of the invention may also contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, antioxidants, and the like, such as, for example, citric acid,
sorbitan monolaurate, triethanolamine oleate, butylalted hydroxytoluene , etc.
Compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propyleneglycol , polyethyleneglycol , glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
One preferable route of administration is oral, using a convenient daily dosage regimen that can be adjusted according to the degree of severity of the disease-state to be treated.
Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders, as for example, cellulose derivatives, starch, alignates, gelatin, polyvinylpyrrolidone, sucrose, and gum acacia, (c) humectants, as for example, glycerol, (d) disintegrating agents, as for example, agar- agar, calcium carbonate, potato or tapioca starch, alginic acid, croscarmellose sodium, complex silicates, and sodium
carbonate, (e) solution retarders, as for example paraffin, (f) absorption accelerators, as for example, quaternary ammonium compounds, (g) wetting agent, as for example, cetyl alcohol, and glycerol monostearate, magnesium stearate and the like (h) adsorbents, as for example, kaolin and bentonite, and (i) lubricants, as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents.
Solid dosage forms as described above can be prepared with coatings and shells, such as enteric coatings and others well known in the art. They may contain pacifying agents, and can also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedded compositions that can be used are polymeric substances and waxes . The active compounds can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients .
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. Such dosage forms are prepared, for example, by dissolving, dispersing, etc., a compound(s) of the invention, or a pharmaceutically acceptable salt thereof, and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol and the like; solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol , 1 , 3-butyleneglycol, dimethylformamide; oils,
in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols and fatty acid esters of sorbitan; or mixtures of these substances, and the like, to thereby form a solution or suspension.
Suspensions, in addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.
Compositions for rectal administrations are, for example, suppositories that can be prepared by mixing the compounds of the present invention with for example suitable non- irritating excipients or carriers such as cocoa butter, polyethyleneglycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt while in a suitable body cavity and release the active component therein.
Dosage forms for topical administration of a compound of this invention include ointments, powders, sprays, and inhalants. The active component is admixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants as may be required. Ophthalmic formulations, eye ointments, powders, and solutions are also contemplated as being within the scope of this invention.
Generally, depending on the intended mode of administration, the pharmaceutically acceptable compositions will contain about 1% to about 99% by weight of a compound (s) of the
invention, or a pharmaceutically acceptable salt thereof, and 99% to 1% by weight of a suitable pharmaceutical excipient. In one example, the composition will be between about 5% and about 75% by weight of a compound (s) of the invention, or a pharmaceutically acceptable salt thereof, with the rest being suitable pharmaceutical excipients.
Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, 18th Ed., (Mack Publishing Company, Easton, Pa., 1990) . The composition to be administered will, in any event, contain a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, for treatment of a disease-state in accordance with the teachings of this invention.
The compounds of the invention, or their pharmaceutically acceptable salts, are administered in a therapeutically effective amount which will vary depending upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of the compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular disease-states, and the host undergoing therapy. The compounds of the present invention can e.g. be administered to a patient at dosage levels in the range of about 0.1 to about 1,000 mg per day. For a normal human adult having a body weight of about 70 kilograms, a dosage in the range of about 0.01 to about 100 mg per kilogram of body weight per day is an example. The specific dosage used, however, can vary. For example, the dosage can depend on a number of factors including the
requirements of the patient, the severity of the condition being treated, and the pharmacological activity of the compound being used. The determination of optimum dosages for a particular patient is well known to one of ordinary skill in the art .
Preparation of compounds of formula (I) :
Scheme 1 depicts a general synthetic route for the preparation of compounds of the present invention and is not intended to be limiting. The reaction may be carried out as a multi component reaction, using reaction conditions that are favorable for product formation:
Scheme 1 (X = S)
More specifically, Scheme 2 and 3 depict examples of the synthesis of further pyrazolo [3 , 4-e] [I74] thiazepine compounds:
Scheme 2
Scheme 3
Specific examples are described subsequently to these general synthetic descriptions so as to allow one skilled in the art to make and use either pyrazolo [3 , 4-e] [1 , 4] thiazepines of the invention.
The following examples serve to more fully describe the manner of using the above-described invention, as well as to set forth the best modes contemplated for carrying out various aspects of the invention. It is understood that these examples in no way serve to limit the true scope of this invention, but rather are presented for illustrative purposes.
Example 1 :
General Pyrazolo [3 , 4-e] [1 , 4] thiazepines Synthesis Equimolar amounts of aldehyde (leq) and amine (leq) were mixed in toluene and refluxed for 2 hours. Subsequently, 1 equivalents of the corresponding mercapto acid was added and the mixture was refluxed for additional 3 hours. Afterwards the reaction was stirred for 16 hours at room temperature, whereby the crude product precipitated. The solid was filtered off and recrystallized in ethyl acetate. The resulting solid was washed with ethyl acetate, water and ether. The final product was dried under high vacuum.
Example 2 :
Synthesis of Pyrazolo [3 , 4-e] [1 , 4] thiazepine carboxylic acid pentafluorophenyl esters according to Scheme 2.
1,5 equivalents of EDCI and 3 equivalents of pentafluorphenol were stirred in absolute DMF for 10 minutes at 00C. Accordingly, 1 equivalent of a carbonic acid of Formula I was added and stirring was continued at 00C for 30 minutes and at room temperature for 16 hours. After the reaction was
completed, the crude product was evaporated to dryness and the final purification was performed by column chromatography on silica with ethyl acetate / dichloromethane mixtures as eluent .
Example 3 :
Synthesis of pyrazolo [3 , 4-e] [1 , 4] thiazepine carboxylic acid amides according to Scheme 2.
The pentafluorphenyl esters from Example 2 were solved in THF and reacted with the corresponding amines during 1 hour at room temperature. The crude product was evaporated to dryness and the final purification was performed by column chromatography on silica with ethyl acetate / methanol mixtures as eluent .
Example 5 :
Synthesis of pyrazolo [3 , 4-e] [1 , 4] thiazepine sulfones or sulfoxides according to Scheme 3.
The pyrazolo [3 , 4-e] [1 , 4] thiazepines of Formula (I) were dissolved in acetic acid and treated with hydrogenperoxide during 1 hour at room temperature. The crude product was evaporated to dryness and the final purification was performed by column chromatography on silica with ethyl acetate / methanol mixtures as eluent .
Example 6 :
According to examples 1, 2 or 3 the following compounds were synthesized and isolated:
Structure Mass Mass found by calculated HPLC-MS
433,58 434,2
360,44 361, 1
Assays
All kinase assays were performed according to literature methods (e.g. as disclosed in Curtin, Cell Notes 2005, 13, 11- 15) known to an expert skilled in the art by using γ~ 33 P ATP. The ATP concentrations were selected to be close to the Michaelis-Menten constant for each specific kinase. Dose- response experiments to determine IC50 inhibition constants are performed by using different inhibitor concentrations in a 96- well plate format. Thus, a radiometric protein kinase was used for measuring the kinase activity of c-Met kinase. All kinase assays were performed in 96 -well FlashPlates from Perkin Elmer (Boston, MA, USA) in a 50 μl reaction volume. The reaction cocktail was pipetted in 4 steps in the following order: 20 μl of assay buffer, 5 μl of ATP solution (in H2O) , 5 μl of test compound (in 10 % DMSO) , 10 μl of substrate / 10 μl of enzyme solution (premixed) . The assay contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na-orthovanadate, 1.2 mM DTT, 50 μg/ml PEG20000, 1 μM [γ-33P] -ATP (approx. 1.5 x 1005 cpm
per well) . For the kinase assays enzyme (100 ng/50μl per well) and substrate poly(Ala, GIu, Lys, Tyr) 6:2:5:1 125 ng/50μl were used per well. The reaction cocktails were incubated at 30° C for 80 minutes. The reaction was stopped with 50 μl of 2 % (v/v) H3PO4, plates were aspirated and washed two times with 200 μl of 0.9 % (w/v) NaCl. Incorporation of 33Pi was determined with a microplate scintillation counter (Microbeta Trilux, WaIlac) . All assays were performed with a BeckmanCoulter/Sagian robotic system.
Compounds of the present invention show a kinase inhibitory activity of below 100 μM in the described assay.
Claims
1. Compound of formula (I)
(D wherein
X is S, SO or SO2;
R1 is a hydrogen atom or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl , heteroaryl , cycloalkyl, alkylcyclo- alkyl, heteroalkylcycloalkyl , heterocycloalkyl , aralkyl or heteroaralkyl radical;
R2 is a hydrogen atom or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcyclo- alkyl, heteroalkylcycloalkyl , heterocycloalkyl, aralkyl or heteroaralkyl radical;
R3 is a hydrogen atom or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcyclo- alkyl , heteroalkylcycloalkyl, heterocycloalkyl, aralkyl or heteroaralkyl radical;
R4 is a hydrogen atom or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcyclo- alkyl, heteroalkylcycloalkyl , heterocycloalkyl , aralkyl or heteroaralkyl radical; and
R5 is a hydrogen atom or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl , heteroaryl, cycloalkyl, alkylcyclo- alkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl or heteroaralkyl radical;
wherein all of the above radicals may optionally be substituted;
or a pharmaceutically acceptable salt, ester, prodrug, solvate or hydrate or a pharmaceutically acceptable formulation thereof.
2. Compound according to claim 1 wherein R1 is an optionally substituted aryl or heteroaryl or an alkyl radical.
3. Compound according to claim 1, wherein R1 is an optionally substituted phenyl radical or an optionally substituted heteroaryl radical containing 5 or 6 ring atoms and 1, 2, 3 or 4 ring-heteroatoms selected from 0, S and N.
4. Compound according to anyone of claims 1 to 3 wherein R2 is an optionally substituted aryl or heteroaryl radical .
5. Compound according to anyone of claims 1 to 3 wherein R2 is an optionally substituted phenyl or naphthyl radical or an optionally substituted heteroaryl radical containing 5 or 6 to 10 ring atoms and 1, 2, 3 or 4 ring-heteroatoms selected from 0, S and N.
6. Compound according to anyone of claims 1 to 5 wherein R3 is a hydrogen atom or a Ci-C4 alkyl radical.
7. Compound according to anyone of claims 1 to 6 wherein R4 is a hydrogen atom or an alkyl, heteroalkyl or heteroalkylcycloalkyl radical .
8. Compound according to anyone of claims 1 to 6 wherein R4 is hydrogen, Ci-C4 alkyl or a group of formula CH2COR8 wherein R8 is hydroxy or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl , heteroaryl, cycloalkyl, alkylcyclo- alkyl, heteroalkylcycloalkyl, heterocycloalkyl , aralkyl or heteroaralkyl radical .
9. Compound according to claim 8 wherein R8 is hydroxy or NH (CH2) pR9, wherein p is 0, 1, 2, 3 or 4 and R9 is an optionally substituted cycloalkyl or heterocycloalkyl radical .
10. A pharmaceutical composition comprising a compound according to anyone of the preceding claims or a pharmaceutically acceptable ester, prodrug, hydrate, solvate or salt thereof, optionally in combination with a pharmaceutically acceptable carrier.
11. Use of a compound or a pharmaceutical composition according to anyone of the preceding claims for the modulation of kinase activity.
12. Use of a compound or a pharmaceutical composition according to anyone of the preceding claims for the treatment and/or prevention of diseases mediated by kinase activity.
13. Use of a compound or a pharmaceutical composition according to anyone of the preceding claims for the treatment and/or prevention of cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09778867A EP2346881A1 (en) | 2008-10-10 | 2009-10-08 | Novel compounds which modulate kinase activity |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08017796 | 2008-10-10 | ||
EP09778867A EP2346881A1 (en) | 2008-10-10 | 2009-10-08 | Novel compounds which modulate kinase activity |
PCT/EP2009/007232 WO2010040527A1 (en) | 2008-10-10 | 2009-10-08 | Novel compounds which modulate kinase activity |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2346881A1 true EP2346881A1 (en) | 2011-07-27 |
Family
ID=40347936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09778867A Withdrawn EP2346881A1 (en) | 2008-10-10 | 2009-10-08 | Novel compounds which modulate kinase activity |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP2346881A1 (en) |
WO (1) | WO2010040527A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201422590A (en) | 2012-09-07 | 2014-06-16 | Abbvie Inc | Heterocyclic nuclear hormone receptor modulators |
WO2014094357A1 (en) | 2012-12-21 | 2014-06-26 | Abbvie Inc. | Heterocyclic nuclear hormone receptor modulators |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3891630A (en) * | 1974-03-04 | 1975-06-24 | Abbott Lab | Substituted pyrazolo{8 3,4-e{9 {8 1,4{9 thiazepines and isoxazolo{8 5,4-e{9 {8 1,4{9 thiazepines |
JP3990718B2 (en) * | 2003-01-09 | 2007-10-17 | ファイザー・インク | Diazepinoindole derivatives as kinase inhibitors |
WO2005009384A2 (en) * | 2003-07-21 | 2005-02-03 | Imclone Systems Incorporated | Egfr tyrosine kinase inhibitors |
-
2009
- 2009-10-08 WO PCT/EP2009/007232 patent/WO2010040527A1/en active Application Filing
- 2009-10-08 EP EP09778867A patent/EP2346881A1/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO2010040527A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2010040527A1 (en) | 2010-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2719428C2 (en) | Indazole compounds as fgfr kinase inhibitors, preparation and use thereof | |
US9718787B2 (en) | Poly (ADP-ribose) polymerase inhibitor | |
CN108383836B (en) | Heterocyclic compounds as MEK inhibitors | |
WO2021129824A1 (en) | New-type k-ras g12c inhibitor | |
US20040266755A1 (en) | Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine | |
WO2001083456A1 (en) | Condensed heteroaryl derivatives | |
US20070149514A1 (en) | Indole-phenylsulfonamide derivatives used as ppar-delta activating compounds | |
AU2013250912A1 (en) | Therapeutic compounds | |
KR20130077390A (en) | 6-amino-3-carboxamidoindazole derivatives as protein kinase inhibitors | |
WO2023061415A1 (en) | Thiadiazolyl derivatives, compositions and uses thereof | |
JP2021500334A (en) | Amine-substituted heterocyclic compounds as EHMT2 inhibitors, salts thereof, and methods for synthesizing them. | |
US20090029983A1 (en) | Novel heterocyclic compounds having anti-hbv activity | |
WO2017118438A1 (en) | Heterocyclic compound used as fgfr inhibitor | |
US20160009729A1 (en) | Nitrogen-containing heterocyclic ring substituted dihydroartemisinin derivatives and use thereof | |
JP3136427B2 (en) | Dibenz [b, f] [1,4] oxazepine-11 (10H) -one | |
US8829039B2 (en) | Dihydroindolinone derivatives | |
KR101145345B1 (en) | 2-Thio-4-amino pyrimidine derivative as an inhibitor of cell proliferation and a process for preparing the same | |
WO2010040527A1 (en) | Novel compounds which modulate kinase activity | |
WO2004080979A1 (en) | Novel 3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl ketone derivatives | |
WO2022184049A1 (en) | Plk4 inhibitor and use thereof | |
WO2001009113A2 (en) | Heterocyclic compounds inhibiting angiogenesis | |
JP2021523134A (en) | 1H-indazole-3-carboxamide compound as a glycogen synthase kinase 3 beta inhibitor | |
JPH05221950A (en) | Benzamide multiple drug resistance reversal agent | |
CN103906751A (en) | [1,3]dioxolo[4,5-g]quinoline-6(5h)thione and [1,3]dioxolo[4,5-g][1,2,4]triazolo[1,5-a]quinoline derivatives as inhibitors of the late sv40 factor (lsf) for use in treating cancer | |
CN112480100B (en) | Pyrrolidone derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20110407 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20140305 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20140625 |